Chimeric binding peptide library screening method by University of Aberdeen.Rowett Institute & McGregor, Duncan
1 11111 11111111 11 IIIIII IIIII 11111 11111 11111 11111 11111 11111 lllll lllll 11111 111111 1111 1111 1111 
US 20080220981Al 
(19) United States
(12) Patent Application Publication
McGregor 
(10) Pub. No.: US 2008/0220981 Al
(43) Pub. Date: Sep. 11, 2008 
(54) CHIMERIC BINDING PEPTIDE LIBRARY
SCREENING METHOD
(75) Inventor: Duncan McGregor, Oldemeldnun 
(GB) 
Correspondence Address: 
CHARLES N. QUINN 
FOX ROTHSCHILD LLP 
2000 MARKET STREET, 10TH FLOOR 
PHILADELPHIA, PA 19103 (US) 
(73) Assignee: 
(21) Appl. No.:
(22) Filed:
Rowett Research Institute, 
Bucksbum (GB) 
11/985,355 
Nov, 13, 2007 
Related U.S. Application Data 
(63) Continuation of application No. 09/486,882, filed on
Mar. 2, 2000, now Pat. No. 7,312,074, filed as appli­
cation No. PCT/GB98/02630 on Sep. 2, 1998.
(30) Foreign Application Priority Data
Sep. 2, 1997 (GB) ................................... 9718455.0 
00450nm 
0.08 +------
0.04 
0.02 
1 
Publication Classification 
(51) Int.Cl.
C40B 30/04
C07K 14/00
C12N 15/00
C07H 21/00
C40B 50/06
(2006.01) 
(2006.01) 
(2006.01) 
(2006.01) 
(2006.01) 
(52) U.S. Cl. ............ 506/9; 530/358; 435/320.1; 506/26; 
536/23.1 
(57) ABSTRACT 
There is described a method ofisolating nucleotide sequences 
encoding target peptides from DNA libraries using DNA 
binding proteins to link the peptide to the sequence which 
encodes it. DNA libraries are prepared from cells encoding 
the protein of interest, or from synthetic DNA, and inserted 
into, or adjacent to, a DNA binding protein in an expression 
vector to create a chimeric fusion protein. Incorporation of 
the vector DNA into a carrier package, during expression of 
the chimeric fusion protein, results in the production of a 
peptide display carrier package (PDCP) displaying the DNA­
bound fusion protein on the external surface of the carrier 
package. Employment of affinity purification techniques 
results in the PDCP particles containing sequences encoding 
the desired peptide to be selected and the desired nucleotide 
sequences obtained therefrom. 
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AAGCTTGO.TGCAAATTCTAT�CAAGGAGAc.\GTC.\TAA ATG MA TAC CTA '.l'l'G CCT .rG GOi GCC GC'l' GGA TTG 
TTCG\ACGT�.CGTTTM�WAGTTCCTCTGTC¼'TATT TAC '.l'l'T ATG GAT AAC � TGC CGT CGG CGi\ CCT AAC 
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437 t, HRE Eco RI ARG ASP ASP GLY GLU GLY ARG GLY GLU VAL CLY SER ttt ttt ,----------, 
ArJi. GAT GAT Gm GAG GGC AGG GGT GM GTG Gm TCT TGA TM TCAGG�T�CCTGAGCTAMATMCACATTCAG TC 
TCT Cl'A crA CCC ere ea; TO: CCA C'lT CAC co:; A� ACT A'IT AGJ.'OlG!CTCACTGGACTCGATTTTATTGTGTAAGTC TTMG 
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lluman Igk constant re�on 
Clone#2 
K R T V A A P S V 
AAACGAACTGTGGCTGCACCATCTGTC 
M AiQ P T T R.. P G Q G T R L D I K R T V A A P S V 
ATGGCCCAGCCC.\CCACGCGTCCGGGCC.UGGGACACGACTGGACATTWCGAACTGTGGCTGCACCATCTGTC 
Clone#� 
M AiQ S H HAS G G GT KV E I K RT VA A PS V
ATGGCCCAGTCCCACCACGCGTCCGGCGGAGGGACCAAGGTGGAGATW.ACGAi\CTGTGGCTGCACCATCTGTC 
Human Igk constant re�on 
F I F P P S D E Q 'L K ., S G T A S V V C L L N N F· Y 
TTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGJi.ATAACTTCTAT 
Clone#2 
F I F P P S D E Q L K S G T A S V V C L L N N F Y 
TTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTAT 
Clone#� 
F I F P P S D E Q L K S G T A S V V C L L N N F Y 
TTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGJi.ATAACTTCTAT 
Patent Application Publication Sep. 11, 2008 Sheet 4 of 9 
· Figure 4 peIB 
US 2008/0220981 Al 
�� mmm���m�w 
AAGCTTGCAT·GCAAATTCTA TTTCAAGGAG ACAGTCATAA ATG AAA TAC CTA TTG CCT ACG GCA GCC 
TTCGAACGTA CGTTTAAGAT AAAGTTCCTC TGTCAGTATT TAC TTT ATG GAT AAC GGA TGC CGT CGG 
68 Sfi I Pst I
ALA GLY LEU LEU LEU LEU ALA ALA GLN PRO ALA MET ALA GLU VAL Gk't LEU GU{ *** *** 
GCT GGA TTG TTA TTA CTC GCG GCC CAG CCG ·· GCC ,AlG GCC GAG GTG CAA CTG CAG TAA TAG . 
CGA CCT AAC AAT AAT GAG CGC CGG GTC GGC CGG TAC CGG·CTC,CAC GTT GAC GTC ATT ATC 
128 Not I 
wALAmrummrum��mmm�m�mrnmm 
GCG GCC GCA GGG GGA GGA GGG TCC ATG GAA TCT GCC AAG GAG ACT CGC 'l\C TGT GCA GTG 
CGC CGG CGT CCC CCT CCT CCC AGG TAC CTT AGA CGG TTC CTC TGA GCG ATG ACA CGT CAC 
188 
CYS ASN ASP TYR ALA SER GLY TYR HIS TYR GLY VAL TRP SER CYS GLU GLY CYS LYS ALA 
TGC l\T GriC �AT GCT TCA GGC TAC CAT TAT GGA GTC TGG TCC TGT GAG GGC TGC AAG GCC 
ACG TTA CTG ATA CGA AGT CCG ATG GTA ATA CCT CAG ACC AGG ACA CTC CCG ACG TTC CGG 
248 
J?HE PHE LYS ARG SER ILE GLN GLY HIS ASN ASP TYR MET CYS PRO ALA THR ASN Gk't CYS 
mmm�mmw�wm�mm�ru�mm�� 
AAG MG TTC TCT TCA TAA GTT CCT GTA TTG CTG ATA TAC ACA GGT CGG TGG TTG GTC ACG 
308 
THR ILE ASP LYS ASN ARG ARG LIS SER CYS GLN ALA CYS ARG LEU ARG LYS CYS TYR GLU 
ACC ATT GAT AAA AAC AGG AGG AAG AGC TGC CAG GCC TGC CGG CTC CGT AAA TGC TAC GAA 
TGG TAA CTA TTT TTG TCC TCC TTC TCG ACG GTC CGG ACG GCC GAG GCA TTT ACG ATG CTT 
368 
VAL GLY MET MET LYS GLY GLY ILE ARG LYS ASP ARG ARG GLY GLY ARG MET LEU LYS HIS 
GTG GGA ATG ATG AAA GGT GGG ATA CGA AAA GAC CGA AGA GGA GGG AGA ATG TTG AAA CAC 
CAC CCT TAC TAC TTT CCA CCC TAT GCT TTT CTG GCT TCT CCT CCC TCT TAC AAC TTT GTG 
428 
LYS ARG GLN ARG ASP ASP GLY GLU GLY ARG GLY GLU VAL GLY SER Ter Ter HRE 1
AAG CGC CAG AGA GAT GAT GGG GAG GGC AGG GGT GAA GTG GGG TCT TGA TAA TCAGGTCAGAG: 
TTC GCG GTC TCT CTA CTA CCC CTC CCG TCC CCA CTT CAC CCC AGA ACT ATT AGTCCAGTCTC1 
491 HRE 1 Sall HRE 2 Eco RI 
CCTGAGCTAAAATAACACATTCAG GTCGAC TTGGGTCAGTCTGACCGGGACAAAGTTAATGTAACCTC GAATTC 
TGGACTCGATTTTATTGTGTAAGTC CAGCTG AACCCAGTCAGACTGGCCCTGTTTCAATTACATTGGAG CTTAAG 
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AAGCTTGCAT.GCAAATTCTA TTTCAAGGAG ACAGTCATAA ATG AAA TAC CTA TTG CCT ACG GCA GCC 
TTCGAACGTA CGTTTAAGAT AAAGTTCCTC TGTCAGTATT TAC TTT ATG GAT AAC GGA TGC CGT CGG 
68 
ALA GLY LEU LEU LEU LEU ALA ALA GLN PRO ALA MET ALA GLU MET GLU SER ALA LYS GLU 
GCT GGA TTG TTA TTA CTC GCG GCC CAG .CCG GCA ATG,GCC GAG ATG GAA TCT GCC AAG GAG 
CGA CCT AAC AAT AAT GAG CGC CGG GTC GGC CGT TAC CGG CTC TAC CTT AGA CGG TTC CTC 
128 
��mmALAmmammmmmmmmmmmm 
��m����m�m�n�mwm��g� 
TGA GCG ATG ACA CGT CAC ACG TTA CTG ATA CGA AGT CCG ATG GTA ATA CCT CAG ACC AGG 
188 
CYS GLU GLY CYS LYS ALA PRE PHE LYS ARG . SER ILE GLN GLY HIS ASN ASP. m MET CYS 
���E��mmm�mmwaw��mmm 
ACA CTC CCG ACG TTC CGG AAG AAG TTC TCT TCA TAA GTT CCT GTA TTG CTG ATA TAC ACA 
248 
�mmm�rumrumrum��mmm�mrnm 
��mm�E�mmwm��w������ 
GGT CGG TGG TTG GTC ACG TGG TAA CTA TTT TTG TCC TCC TTC TCG ACG GTC CGG ACG GCC 
308 
LEU ARG LYS CYS TYR GLU m GLY MET MET LYS GLY GLY ILE ARG LYS ASP ARG ARG GLY 
CTC CGT AAA TGC TAC GAA GTG GGA ATG ATG AAA GGT GGG ATA CGA AAA GAC CGA AGA GGA 
GAG � TTT ACG ATG CTT CAC CCT TAC TAC TTT CCA CCC TAT GCT TTT CTG GCT TCT CCT . 
368 
w�m�rumm��mmmm�mmm�mm 
GGG AGA ATG TTG AAA CAC AAG CGC CAG AGA GAT GAT GGG GAG GGC AGG GGT GAA GTG GGG 
CCC TCT TAC AAC TTT GTG TTC GCG GTC TCT CTA CTA CCC CTC CCG TCC CCA CTT CAC CCC 
428 .---__ ___, Sfi I PstI Not I 
·SER GLY GLY GLY GLY SER ALA GLN PRO ALA LEU LEU GLN LEU ALA mm TER
TCT GGG GGA GGA GGG TCG GCC CAG CCG GCC CTC CTG CAG CTG GCG GCC GCA TAACTGATTG
WUUt.�...it./LL-Xx..x....!:.A:uu CGG GTC GGC CGG GAG GAC GTC GAC CGC CGG CGT ATTGACTAAC 
489Sall ....----------_,Eco RI 
AGTCGAC�TG GGTCAGTCTG ACCGGGACAA AGTTAATGTA ACCTC GAATTC 
TCAGCTG �C CCAGTCAGAC TGGCCCTGTT TCAATTACAT TGGAG CTTAAG 
HRE 
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Q V Q L Q Q S G G G V V Q P G R S L 
CAGGTACAGCTGCAGCAGTCAGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTG 
GTCCATGTCGACGTCGTCAGTCCCCCTCCGCACCAGGTCGGACCCTCCAGGGAC 
R L S C A A S G F P F S T Y G M H W 
AGACTCTCCTGTGCAGCCTCGGGATTCCCCTTTAGTACT'l!ATGGCATGCACTGG 
TCTGAGAGGACACGTCGGAGCCCTAAGGGGAAATCATGAATACCGTACGTGACC 
R Q A V P G K G L E W V A V I S Y D 
CGCCAGGCTGTCCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTMATCATATGAT 
GCGGTCCGACAGGGTCCGTTCCCCGACCTCACCCACCGT�TA 
G S N K Y Y A D S V K G R F T I S R 
GGAAG�!ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGA 
CCTTCATIA'l"l'TATGATGCGTCTGAGGCACTTCCCGGCTAAGTGGTAGAGGTCT 
D N S K N T L Y L Q M N S L R A E D 
GACAATTCCAAGAACACGTTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGAC 
CTGTTAAGGTTCTTGTGCAACATAGACGTTTACTTGTCGGACTCTCGACTCCTG 
T A V Y Y C A R D L D P T R Y S S G 
ACGGCTGTGTATTACTGTGCGAGAGATTTAGACCCCACCAGG�TGGC 
TGCCGACACATAATGACACGCTCTCTAAATCTGGGGTGGTCCATATCGTCACCG 
W D T D Y W G Q G H L V T V S S 
TGGGACACTGACTACTGGGGCCAGGGGCACCTGGTCACTGTCTCCTCA 
ACCCTGTGACTGA.TGACCCCGGTCCCCGTGGACCAGTGACAGAGGAGT 
UGHTCHAIN 
E T T L T Q S P G T L S L S P G E R 
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCGGGGGAAAGA 
CTTTGCTGTGAGTGCGTCAGAGGTCCGTGGGACAGAAACAGAGGCCCCCTTTCT 
A T  L S  C R  A S  Q N. I G S  S S L  A W
GCCACCCTCTCCTGCAGGGCCAGTCAGAATATTGGCAGCAGCTCCT'I!AGCCTGG 
CGGTGGGAGAGGACGTCCCGGTCAGTC'l'TATAACCGTCGTCGAGGAA!rCGGACC 
Y Q Q K P G Q A P R L L I Y G A S T 
TACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACC 
ATGGTTGTCTTTGGACCGGTCCGAGGGTCCGAGGAGTAGATACCACGTAGGTGG 
R A T G F S G S G S G T Q F T L T I 
AGGGCCACTGGTTTCAGTGGCAGTGGGTCAGGGACACAATTCACTCTCACCATC 
TCCCGGTGACCAAAGTCACCGTCACCCAGTCCCTGTGTTAAGTGAGAGTGGTAG 
I P A R S S L Q S E D F A V Y Y C Q 
· ATCCCAGCCAGGAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTc:AG
TAGGGTCGGTCCTCGTCGGACGTCAGACTTCTAAAACGTCAAATAATGACAGTC
Q Y N F W P F T F G P G T K L E I K 
CAG'XATAATTI'CTGGCCATTCACTTTTGGCCCTGGGACCAAGCTGGAGATCAAA 
GTCAT.ATTAAAGACCGGTAAGTGAAAACCGGGACCCTGGTTCGACCTCTAGTTT 
R 
CGT 
GCA 
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CHIMERIC BINDING PEPTIDE LIBRARY 
SCREENING METHOD 
[0001] The present invention relates generally to methods 
for screening nucleotide libraries for sequences that encode 
peptides of interest. 
[0002] Isolating an unknown gene which encodes a desired 
peptide from a recombinant DNA library can be a difficult 
task. The use of hybridisation probes may facilitate the pro­
cess, but their use is generally dependent on knowing at least 
a portion of the sequence of the gene which encodes the 
protein. When the sequence is not known, DNA libraries can 
be expressed in an expression vector, and antibodies have 
been used to screen for plaques or colonies displaying the 
desired protein antigen. This procedure has been useful in 
screening small libraries, but rarely occurring sequences 
which are represented in less than about 1 in 105 clones ( as is
the case with rarely occurring cDNA molecules or synthetic 
peptides) can be easily missed, making screening libraries 
larger than 106 clones at best laborious and difficult. Methods 
designed to address the isolation of rarely occurring 
sequences by screening libraries of 106 clones have been 
developed and include phage display methods and Lael 
fusion phage display, discussed in more detail below. 
[0003] Phage display methods. Members of DNA libraries 
which are fused to the N-terminal end of filamentous bacte­
riophage pIII and p VIII coat proteins have been expressed 
from an expression vector resulting in the display of foreign 
peptides on the surface of the phage particle with the DNA 
encoding the fosion protein packaged in the phage particle 
(Smith G. P., 1985, Science 228: 1315-1317).111e expression 
vector can be the bacteriophage genome itself, or a phagemid 
vector, into which a bacteriophage coat protein has been 
cloned. In the latter case, the host bacterium, containing the 
phagemid vector, must be co-infected with autonomously 
replicating bacteriophage, termed helper phage, to provide 
the full complement of proteins necessary to produce mature 
phage particles. The helper phage normally has a genetic 
defect in the origin of replication which results in the prefer­
ential packaging of the phagemid genome. Expression of the 
fusion protein following helper phage infection, allows incor­
poration of both fusion protein and wild type coat protein into 
the phage particle during assembly. Libraries of fusion pro­
teins incorporated into phage, can then be selected for binding 
members against targets of interest (ligands). Bound phage 
can then be allowed to reinfect Escherichia coli (E. coli) 
bacteria and then amplified and the selection repeated, result­
ing in the enriclunent of binding members (Parmley, S. F., & 
Smith, G. P. 1988., Gene 73: 305-318; Barrett R. W. et al., 
1992, Analytical Biochemistry 204: 357-364 Williamson et 
al., Proc. Natl. Acad. Sci. USA, 90: 4141-4145; Marks et al., 
1991, J. Mo!. Biol. 222: 581-597). 
[0004] Several publications describe this method. For 
example, U.S. Pat. No. 5,403,484 describes production of a 
chimeric protein formed from the viral coat protein and the 
peptide of interest. In this method at least a functional portion 
of a viral coat protein is required to cause display of the 
chimeric protein or a processed form thereof on the outer 
surface of the virus. In addition, U.S. Pat. No. 5,571,698 
describes a method for obtaining a nucleic acid encoding a 
binding protein, a key component of which comprises pre­
paring a population of an1plifiable genetic packages which 
have a genetically detem1ined outer surface protein, to cause 
1 
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the display of the potential binding domain on the outer 
surface of the genetic package. The genetic packages are 
selected from the group consisting of cells, spores and 
viruses. For example when the genetic package is a bacterial 
cell, the outer surface transport signal is derived from a bac­
terial outer surface protein, and when the genetic package is a 
filamentous bacteriophage, the outer surface transport signal 
is provided by the gene pIII (minor coat protein) or pVIII 
(major coat protein) of the filamentous phage. 
[0005] WO-A-92/01047 and WO-A-92/20791 describe 
methods for producing multimeric specific binding pairs, by 
expressing a first polypeptide chain fused to a viral coat 
protein, such as the gene pIII protein, of a secreted replicable 
genetic display package (RGDP) which displays a polypep­
tide at the surface of the package, and expressing a second 
polypeptide chain of the multimer, and allowing the two 
chains to come together as part of the RGDP. 
[0006] Lael fosion plasmid display. This method is based 
on the DNA binding ability of the lac repressor. Libraries of 
random peptides are fused to the lad repressor protein, nor­
mally to the C-terminal end, through expression from a plas­
mid vector carrying the fusion gene. Linkage of the Lael­
peptide fusion to its encoding DNA occurs via the lacO 
sequences-on the plasmid, forming a stable peptide-Lacl­
peptide complex. These complexes are released from their 
host bacteria by cell lysis, and peptides of interest isolated by 
affinity purification on an immobilised target. The plasmids 
thus isolated can then be reintroduced into E. coli by elec­
troporation to amplify the selected population for additional 
rounds of screening (Cull, M. G. et al. 1992. Proc. Natl.Acad. 
Sci. U.S.A. 89:1865-1869). 
[0007] U.S. Pat. No. 5,498,530 describes a method for con­
structing a library of random peptides fused to a DNA binding 
protein in appropriate host cells and culturing the host cells 
under conditions suitable for expression of the fusion proteins 
intra-cellularly, in the cytoplasm of the host cells. This 
method also teaches that the random peptide is located at the 
carboxy tenninus of the fusion protein and that the fusion 
protein-DNA complex is released from the host cell by cell 
lysis. No method is described for the protection of the DNA 
from degradation once released from the lysed cell. Several 
DNA binding proteins are claimed but no examples are shown 
except lad. 
[0008] There remains a need for methods of constructing 
peptide libraries in addition to the methods described above. 
For instance, the above methods do not permit production of 
secreted peptides with a free carboxy terminus. The present 
invention describes an alternative method for isolating pep­
tides of interest from libraries and has significant advantages 
over the prior art methods. 
[0009] In general tenns, the present invention provides a 
method for screening a nucleotide library (usually a DNA 
library) for a nucleotide sequence which encodes a target 
peptide of interest. The method involves physically linking 
each peptide to a polynucleotide including the specific nucle­
otide sequence encoding that peptide. Linkage of a peptide to 
its encoding nucleotide sequence is achieved via linkage of 
the peptide to a nucleotide binding domain. A bifunctional 
chimeric protein with a nucleotide binding domain and a 
library member or target peptide (preferably with a function 
of interest) is thus obtained. The peptide of interest is bound 
to the polynucleotide encoding that peptide via the nucleotide 
binding domain of the chimeric protein. 
US 2008/0220981 Al 
(0010] The polynucleotide-chimeric protein complex is 
then incorporated within a peptide display carrier package 
(PDCP), protecting the polynucleotide from subsequent deg­
radation, while displaying the target peptide portion on the 
outer surface of the peptide display carrier package (PDCP). 
(0011] Thus, in one aspect, the present invention provides a 
peptide display carrier package (PDCP), said package com­
prising a polynucleotide-chimeric protein complex wherein 
the chimeric protein has a nucleotide binding portion and a 
target peptide portion, wherein said polynucleotide com­
prises a nucleotide sequence motif which is specifically 
bound by said nucleotide binding portion, and wherein at 
least the chimeric protein encoding portion of the polynucle­
otide not bound by the nucleotide binding portion of the 
chimeric protein is protected. 
(0012] In one embodiment the polynucleotide is protected 
by a protein which binds non-specifically to naked polynucle­
otide. Examples include viral coat proteins, many of which 
are well-known in the art. Where the chosen viral coat protein 
requires an initiation sequence to commence general binding 
to the polynucleotide, this will be provided on the polynucle­
otide at appropriate location(s). A preferred coat protein is 
coat protein from a bacteriophage, especially M13. 
(0013] Generally, the nucleic binding portion of the chi­
meric protein is selected for its specificity for the nucleotide 
sequence motif present in the recombinant polynucleotide 
encoding the chimeric protein. 
(0014] Optionally, the nucleotide sequence motif may be 
an integral part of the protein encoding region of the poly­
nucleotide. Alternatively, and more usually. the motif may be 
present in a non-coding region of the polynucleotide. For the 
purposes of this invention, all that is required is for the motif 
to be located on the polynucleotide such that the nucleotide 
binding portion of the chimeric protein is able to recognise 
and bind to it. Desirably the polynucleotide-chimeric protein 
complex has a dissociation constant of at least one hour. 
(0015] Optionally, the recombinant polynucleotide may 
comprise two or more nucleotide sequence motifs, each of 
which will be bound by a chimeric protein molecule. Prefer­
ably. the motifs are positioned along the length of the poly­
nucleotide to avoid steric hindrance between the bound chi­
meric proteins. 
(0016] Preferably, the nucleotide sequence motif is not 
affected by the presence of additional nucleotide sequence 
(e.g., encoding sequence) at its 5' and/or 3' ends. Thus the 
chimeric fusion protein may include a target peptide portion 
at its N tem1inal end, at its C terminal end or may include two 
target peptide portions (which may be the same or different) 
at each end of the nucleotide binding portion, ie at both the N 
and C terminal ends of the chimeric protein. For example one 
target peptide may be an antibody of known specificity and 
the other peptide may be a peptide of potential interest. 
(0017] Desirably the target peptide portion of the chimeric 
protein is displayed externally on the peptide display carrier 
package, and is thus available for detection, reaction and/or 
binding. 
(0018] In more detail the PDCP may be composed two 
distinct elements: 
(0019] a. A polynucleotide-chimeric protein complex. 
This links the displayed target peptide portion to the 
polynucleotide encoding that peptide portion through a 
specific polynucleotide binding portion. The nucleotide 
sequence encoding the chimeric protein, and the specific 
nucleotide sequence motif recognised by the nucleotide 
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binding portion of the chimeric protein must be present 
on a segment of polynucleotide which can be incorpo­
rated into the PDCP; and 
(0020] b. A protective coat. This may be supplied by a 
replicable carrier or helper package capable of independent 
existence. Alternatively, a coat protein could be encoded by 
the recombinant polynucleotide of the invention. The protec­
tive coat for the polynucleotide-chimeric protein complex 
may be composed of a biological material such as protein or 
lipid, but the protective coat is not required for linking the 
target peptide to the polynucleotide encoding that peptide. 
The protective coat must allow the display of the target pep­
tide portion of the chimeric protein on its outer surface. The 
carrier or helper package may also provide the mechanism for 
releasing the intact PDCP from host cells when so required. 
By way of example, when a bacteriophage is the replicable 
carrier package, a protein coat of the bacteriophage surrounds 
the polynucleotide-chimeric protein complex to form the 
PDCP, which is then extruded from the host bacterial cell. 
(0021] The invention described herein demonstrates that 
peptides fused to a nucleotide binding domain can be dis­
played externally, even through a bacteriophage carrier pack­
age protein coat, while still bound to the polynucleotide 
encoding the displayed peptide. 
(0022] The present invention also provides a recombinant 
polynucleotide comprising a nucleotide sequence encoding a 
chimeric protein having a nucleotide binding portion oper­
ably linked to a target peptide portion, wherein said poly­
nucleotide includes a specific nucleotide sequence motif 
which is bound by the nucleotide binding portion of said 
chimeric protein and further encoding a non-sequence-spe­
cific nucleotide binding protein. 
(0023] Desirably, the recombinant polynucleotide is a 
recombinant expression system, able to express the chimeric 
protein when placed in a suitable environment, for example a 
compatible host cell. After its expression, the chimeric pro­
tein binds to the specific nucleotide sequence (motif) present 
in the polynucleotide comprising the nucleotide sequence 
encoding the chimeric protein. 
(0024] Optionally there may be a linker sequence located 
between the nucleotide sequence encoding the nucleotide 
binding portion and the polynucleotide inserted into the 
restriction enzyme site of the construct. 
(0025] Desirably the nucleotide binding portion is a DNA 
binding domain of an oestrogen or progesterone receptor, or 
a functional equivalent thereof. Examples of sequences 
encoding such nucleotide binding portions are set out in SEQ 
ID Nos 11 and 13. 
(0026] The term "expression system" is used herein to refer 
to a genetic sequence which includes a protein-encoding 
region and is operably linked to all of the genetic signals 
necessary to achieve expression of that region. Optionally. the 
expression system may also include regulatory elements, 
such as a promoter or enhancer to increase transcription and/ 
or translation of the protein encoding region or to provide 
control over expression. The regulatory elements may be 
located upstream or downstream of the protein encoding 
region or within the protein encoding region itself. Where two 
or more distinct protein encoding regions are present these 
may use common regulatory element(s) or have separate 
regulatory element(s ). 
(0027] Generally, the recombinant polynucleotide 
described above will be DNA. Where the expression system is 
based upon an M13 vector, usually the polynucleotide bind-
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ing portion of the expressed chimeric portion will be single­
stranded DNA. However, other vector systems may be used 
and the nucleotide binding portion may be selected to bind 
preferentially to double-stranded DNA or to double or single­
stranded RNA, as convenient. 
[0028] Additionally the present invention provides a vector 
containing such a recombinant expression system and host 
cells transformed with such a recombinant expression system 
( optionally in the form of a vector). 
[0029] Whilst the recombinant polynucleotide described 
above fonns an important part of the present invention, we are 
also concerned with the ability to screen large ( e.g. of at least 
105 members, for example 106 or even 10 7 members) libraries 
of genetic material. One of the prime considerations therefore 
is the provision of a recombinant genetic construct into which 
each member of said library can individually be incorporated 
to form the recombinant polynucleotide described above and 
to express the chimeric protein thereby encoded (the target 
peptide of which is encoded by the nucleotide library member 
incorporated into the construct). 
[0030] Thus viewed in a further aspect the present invention 
provides a genetic construct or set of genetic constructs com­
prising a polynucleotide having a sequence which includes: 
[0031] i) a sequence encoding a nucleotide binding portion 
able to recognise and bind to a specific sequence motif; 
[0032] ii) the sequence motif recognised and bound by the 
nucleotide binding portion encoded by (i); 
[0033] iii) a restriction enzyme site which pem1its insertion 
of a polynucleotide, said site being designed to operably 
link said polynucleotide to the sequence encoding the 
nucleotide binding portion so that expression of the oper­
ably linked polynucleotide sequences yields a chimeric 
protein; and 
[0034] iv) a sequence encoding a nucleotide binding pro-
tein which binds non-specifically to naked polynucleotide. 
(0035] Optionally there may be a linker sequence located 
between the nucleotide sequence encoding the nucleotide 
binding portion and the sequence of the polynucleotide from 
the library inserted into the restriction enzyme site of the 
construct. 
[0036] Desirably the nucleotide binding portion is a DNA 
binding domain of an oestrogen or progesterone receptor, or 
a functional equivalent thereof. Examples of sequences 
encoding such nucleotide binding portions are set out in SEQ 
ID Nos 11 and 13. 
(0037] Suitable genetic constructs according to the inven­
tion include pDM12, pDM14 and pDM16, deposited at 
NCIMB on 28 Aug. 1998 under Nos NCIMB 40970, NCIMB 
40971 and NCIMB 40972 respectively. 
(0038] It is envisaged that a conventionally produced 
genetic library may be exposed to the genetic construct(s) 
described above. Thus, each individual member of the genetic 
library will be separately incorporated into the genetic con­
struct and the library will be present in the form of a library of 
recombinant polynucleotides (as described above), usually in 
the forn1 of vectors, each recombinant polynucleotide includ­
ing as library member. 
[0039] Thus, in a further aspect, the present invention pro­
vides a library of recombinant polynucleotides ( as defined 
above) wherein each polynucleotide includes a polynucle­
otide obtained from a genetic library and which encodes the 
target peptide portion of the chimeric protein expressed by the 
recombinant polynucleotide. 
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[0040] Optionally, the chimeric protein may further include 
a linker sequence located between the nucleotide binding 
portion and the target peptide portion. The linker sequence 
will reduce steric interference between the two portions of the 
protein. Desirably the linker sequence exhibits a degree of 
flexibility. 
[0041] Also disclosed are methods for constructing and 
screening libraries of PDCP particles, displaying many dif­
ferent peptides, allowing the isolation and identification of 
particular peptides by means of affinity techniques relying on 
the binding activity of the peptide of interest. The resulting 
polynucleotide sequences can therefore be more readily iden­
tified, re-cloned and expressed. 
[0042] A method of constructing a genetic library, said 
method comprising: 
[0043] a) constructing multiple copies of a recombinant 
vector comprising a polynucleotide sequence which 
encodes a nucleotide binding portion able to recognise and 
bind to a specific sequence motif ( and optionally also 
including the specific sequence motif); 
(0044] b) operably linking each said vector to a polynucle­
otide encoding a target polypeptide, such that expression of 
said operably linked vector results in expression of a chi­
meric protein comprising said target peptide and said 
nucleotide binding portions; wherein said multiple copies 
of said operably linked vectors collectively express a 
library of target peptide portions; 
[0045] c) transforming host cells with the vectors of step b ); 
(0046] d) culturing the host cells of step c) under conditions 
suitable for expression of said chimeric protein; 
(0047] e) providing a recombinant polynucleotide com­
prising the nucleotide sequence motif specifically recogn­
ised by the nucleotide binding portion and exposing this 
polynucleotide to the chimeric protein of step d) to yield a 
polynucleotide-chimeric protein complex; and 
[0048] f) causing production of a non-sequence-specific 
moiety able to bind to the non-protected portion of the 
polynucleotide encoding the chimeric protein to fom1 a 
peptide display carrier package. 
[0049] The present invention further provides a method of 
screening a genetic library, said method comprising: 
(0050] a) exposing the polynucleotide members of said 
library to multiple copies of a genetic construct comprising 
a nucleotide sequence encoding a nucleotide binding por­
tion able to recognise and bind to a specific sequence motif, 
under conditions suitable for the polynucleotides of said 
library each to be individually ligated into one copy of said 
genetic construct, to create a library of recombinant poly­
nucleotides; 
[0051] b) exposing said recombinant polynucleotides to a 
population of host cells, under conditions suitable for 
transformation of said host cells by said recombinant poly­
nucleotides; 
[0052] c) selecting for transfom1ed host cells; 
[0053] d) exposing said transformed host cells to condi­
tions suitable for expression of said recombinant poly­
nucleotide to yield a chimeric protein; and 
(0054] e) providing a recombinant polynucleotide com­
prising the nucleotide sequence motif specifically recogn­
ised by the nucleotide binding portion and exposing this 
polynuclcotide to the chimeric protein of step d) to yield a 
polynucleotide-chimeric protein complex; 
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(0055] f) protecting any exposed portions of the polynucle­
otide in the complex of step e) to fom1 a peptide display 
carrier package; and 
(0056] g) screening said peptide display carrier package to 
select only those packages displaying a target peptide por­
tion having the characteristics required. 
(0057] Desirably in step a) the genetic constrnct is pDM12, 
pDM14 or pDM16. 
(0058] Desirably in step f) the peptide display package 
carrier is extruded from the transformed host cell without 
lysis of the host cell. 
(0059] Generally the transformed host cells will be plated 
out or otherwise divided into single colonies following trans­
formation and prior to expression of the chimeric protein. 
(0060] The screening step g) described above may look for 
a particular target peptide either on the basis of function ( e.g. 
enzymic activity) or structure (e.g. binding to a specific anti­
body). Once the peptide display carrier package is observed 
to include a target peptide with the desired characteristics, the 
polynucleotide portion thereof (which of course encodes the 
chimeric protein itself) can be amplified, cloned and other­
wise manipulated using standard genetic engineering tech­
niques. 
(0061] The current invention differs from the prior art 
teaching of the previous disclosures U.S. Pat. No. 5,403,484 
and U.S. Pat. No. 5,571,698, as the invention does not require 
outer surface transport signals, or functional portions of viral 
coat proteins, to enable the display of chimeric binding pro­
teins on the outer surface of the viral particle or genetic 
package. 
(0062] The current invention also differs from the teaching 
ofWO-A-92/01047 and WO-A-92/20791, as no component 
of a secreted replicable genetic display package, or viral coat 
protein is required, to enable display of the target peptide on 
the outer surface of the viral particle. 
(0063] The current invention differs from the teaching of 
U.S. Pat. No. 5,498,530, as it enables the display of chimeric 
proteins, linked to the polynucleotide encoding the chimeric 
protein, extra-cellularly, not in the cytoplasm of a host cell. In 
the current invention the chimeric proteins are presented on 
the outer surface of a peptide display carrier package (PDCP) 
which protects the DNA encoding the chimeric protein, and 
does not require cell lysis to obtain access to the chimeric 
protein-DNA complex. Finally, the current invention does not 
rely upon the lacl DNA binding protein to form the chimeric 
protein-DNA complex. 
(0064] In one embodiment of the invention, the nucleotide 
binding portion of the chimeric protein comprises a DNA 
binding domain from one or more of the nuclear steroid 
receptor family of proteins, or a functional equivalent of such 
a domain. Particular examples include (but are not limited to) 
a DNA binding domain of the oestrogen receptor or the 
progesterone receptor, or functional equivalents thereof. 
These domains can recognise specific DNA sequences, 
termed hormone response elements (HRE), which can be 
bmmd as both double and single-stranded DNA. The DNA 
binding domain of such nuclear steroid receptor proteins is 
preferred. 
(0065] The oestrogen receptor is especially referred to 
below by way of example, for convenience since: 
( a) The oestrogen receptor is a large multifunctional polypep­
tide of 595 amino acids which functions in the cytoplasm and
nucleus of eukaryotic cells (Green et al., 1986, Science 231:
1150-1154). A minimal high affiuity DNA binding domain
4 
Sep. 11, 2008 
(DBD) has been defined between amino acids 176 and 282 
(Mader et al., 1993, Nucleic Acids Res. 21: 1125-1132). The 
functioning of this domain (i.e. DNA binding) is not inhibited 
by the presence of non-DNA binding domains at both the N 
and C terminal ends of this domain. in the full length protein. 
(b) The oestrogen receptor DNA binding domain fragment
(amino acids 176-282) has been expressed in E. coli and 
shown to bind to the specific double stranded-DNA oestrogen
receptor target HRE nucleotide sequence, as a dimer with a
similar affinity (0.5 nM) to the parent molecule (Murdoch et
al. 1990, Biochemistry 29: 8377-8385; Mader et al., 1993,
Nucleic Acids Research 21: 1125-1132). DBD dimerization
on the surface of the PDCP should result in two peptides
displayed per particle. This bivalent display can aid in the
isolation of low affinity peptides and peptides that are
required to form a bivalent conformation in order to bind to a
particular target, or activate a target receptor. The oestrogen
receptor is capable of binding to its 38 base pair target HRE
sequence, consensus sequence:
SEQ ID No 77 
1) 5'-TCAGGTCAGAGTGACCTGAGCTAAAATAACACATTCAG-3' 
( "minus strand") , 
and 
SEQ ID No 78 
2) 3'-AGTCCAGTCTCACTGGACTCGATTTTATTGTGTAAGTC-5' 
( "plus strand"),
with high affinity and specificity, under the salt and pH con­
ditions nomially required for selection of binding peptides. 
Moreover, binding affinity is increased 60-fold for the single­
stranded coding, or "plus", strand (i.e. SEQ ID No 78) of the 
HRE nucleotide sequence over the double stranded form of 
the specific target nucleotide sequence (Peale et al. 1988, 
Proc. Natl. Acad. Sci. USA 85: 1038-1042; Lannigan & 
Notides, 1989, Proc. Natl. Acad. Sci. USA 86: 863-867). 
(0066] In an embodiment of the invention where the DNA 
binding component of the peptide display carrier package is 
the oestrogen receptor, the nucleotide (DNA) binding por­
tion-contains a minimum sequence of amino acids 17 6-282 of 
the oestrogen receptor protein. In addition, the consensus 
oestrogen receptor target HRE sequence is cloned in such a 
way that if single stranded DNA can be produced-then the 
coding, or "plus", strand of the oestrogen receptor HRE 
nucleotide sequence is incorporated into single-stranded 
DNA. An example of a vector suitable for this purpose is 
pUC119 (see Viera et al., Methods in Enzymology, Vol 153, 
pages 3-11, 1987). 
(0067] In a preferred embodiment of the invention a peptide 
display carrier package (PDCP) can be assembled when a 
bacterial host cell is transfonned with a bacteriophage vector, 
which vector comprises a recombinant polynucleotide as 
described above. The expression vector will also comprise the 
specific nucleotide motif that can be bound by the nucleotide 
binding portion of the chimeric protein. Expression of recom­
binant polynucleotide results in the production of the chi­
meric protein which comprises the target peptide and the 
nucleotide binding portion. The host cell is grown under 
conditions suitable for chimeric protein expression and 
assembly of the bacteriophage particles, and the association 
of the chimeric protein with the specific nucleotide sequence 
in the expression vector. In this embodiment, since the vector 
is a bacteriophage, which replicates to produce a single­
stranded DNA, the nucleotide binding portion preferably has 
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an affinity for single-stranded DNA. Incorporation of the 
vector single-stranded DNA-chimeric protein complex into 
bacteriophage particles results in the assembly of the peptide 
display carrier package (PDCP), and display of the target 
peptide on the outer surface of the PDCP. 
[0068] In this embodiment both of the required elements 
for producing peptide display carrier packages are contained 
on the same vector. Incorporation of the DNA-chimeric pro­
tein complex into a peptide display carrier package (PDCP) is 
preferred as DNA degradation is prevented, large numbers of 
PDCPs are produced per host cell, and the PDCPs are easily 
separated from the host cell without recourse to cell lysis. 
[0069] In a more preferred embodiment, the vector of the is 
a phagemid vector (for example pUC119) where expression 
of the chimeric protein is controlled by an inducible promoter. 
In this embodiment the PDCP can only be assembled follow­
ing infection of the host cell with both phagemid vector and 
helper phage. The transfected host cell is then cultivated 
under conditions suitable for chimeric protein expression and 
assembly of the bacteriophage particles. 
[0070] In this embodiment the elements of the PDCP are 
provided by two separate vectors. The phagemid derived 
PDCP is superior to phagemid derived display packages dis­
closed in WO-A-92/01047 where a proportion of packages 
displaying bacteriophage coat protein fusion proteins will 
contain the helper phage DNA, not the fusion protein DNA 
sequence. In the current invention, a PDCP can display the 
chimeric fusion protein only when the package contains the 
specific nucleotide motif recognised by the nucleotide bind­
ing portion. In most embodiments this sequence will be 
present on the same DNA segment that encodes the fusion 
protein. In addition, the prior art acknowledges that when 
mutant and wild type proteins are co-expressed in the same 
bacterial cell, the wild type protein is produced preferentially. 
Thus, when the wild type helper phage, phage display system 
of WO-A-92/01047 is used, both wild type gene pIII and 
target peptide-gene pIII chimeric proteins are produced in the 
same cell. The result of this is that the wild type gene pIII 
protein is preferentially packaged into bacteriophage par­
ticles, over the chimeric protein. In the current invention, 
there is no competition with wild type bacteriophage coat 
proteins for packaging. 
[0071] Desirably the target peptide is displayed in a loca­
tion exposed to the external environment of the PDCP, a±ter 
the PDCP particle has been released from the host cell with­
out recourse to cell lysis. The target peptide is then accessible 
for binding to its ligand. Thus, the target peptide may be 
located at or near the N-tcrminus or the C-terminus of a 
nucleotide binding domain, for example the DNA binding 
domain of the oestrogen receptor. 
[0072] The present invention also provides a method for 
screening a DNA library expressing one or more polypeptide 
chains that are processed, folded and assembled in the peri­
plasmic space to achieve biological activity. The PDCP may 
be assembled by the following steps: 
(a) Constrnction ofN- or C-terminal DBD chimeric protein
fusions in a phagemid vector.
(0073] (i) When the target peptide is located at the N-ter­
minus of the nucleotide binding portion, a library of 
DNA sequences each encoding a potential target peptide 
is cloned into an appropriate location of an expression 
vector (i.e. behind an appropriate promoter and transla­
tion sequences and a sequence encoding a signal peptide 
leader directing transport of the downstream fusion pro-
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tein to the periplasmic space) and upstream of the 
sequence encoding the nucleotide binding portion. In a 
preferred embodiment the DNA sequence(s) of interest 
may be joined, by a region of DNA encoding a flexible 
amino acid linker, to the 5'-end of an oestrogen receptor 
DBD. 
[0074] (ii) Alternatively, when the target peptide is 
located at the C-terminus of the nucleotide binding 
domain, a library of DNA sequences each encoding a 
potential target peptide is cloned into the expression 
vector so that the nucleotide sequence coding for the 
nucleotide binding portion is upstream of the cloned 
DNA target peptide encoding sequences, said nucleotide 
binding portion being positioned behind an appropriate 
promoter and translation sequences and a sequence 
encoding a signal peptide leader directing transport of 
the downstream fusion protein to the pcriplasmic space. 
In a preferred embodiment, DNA sequence(s) ofinterest 
may be joined, by a region of DNA encoding a flexible 
amino acid linker oestrogen receptor DBD DNA 
sequence. 
[0075] Located on the expression vector is the specific HRE 
nucleotide sequence recognised, and bound, by the oestrogen 
receptor DBD. In order to vary the number of chimeric pro­
teins displayed on each PDCP particle, this sequence can be 
present as one or more copies in the vector. 
(b) Incorporation into the PDCP. Non-lytic helper bacterioph­
age infects host cells containing the expression vector. Pre­
ferred types of bacteriophage include the filamentous phage
fd, fl and M13. In a more preferred embodiment the bacte­
riophage may be M13K07.
(0076] The protein(s) of interest are expressed and trans­
ported to the periplasmic space, and the properly assembled
proteins are incorporated into the PDCP particle by virtue of
the high affinity interaction of the DBD with the specific
target nucleotide sequence present on the phagemid vector
DNA which is naturally packaged into phage particles in a
single-stranded fonn. The high affinity interaction between
the DBD protein and its specific target nucleotide sequence
prevents displacement by bacteriophage coat proteins result­
ing in the incorporation of the protein( s) of interest onto the
surface of the PDCP as it is extruded from the cell.
( c) Selection of the peptide of interest. Particles which display
the peptide of interest arc then selected from the culture by
affinity enrichment techniques.
[0077] This is accomplished by means of a ligand specific
for the protein of interest, such as an antigen if the protein of
interest is an antibody. The ligand may be presented on a solid
surface such as the surface of an ELISA plate, or in solution.
Repeating the affinity selection procedure provides an enrich­
ment of clones encoding the desired sequences, which may
then be isolated for sequencing, further cloning and/or
expression.
(0078] Numerous types oflibraries of peptides fused to the
DBD can be screened under this embodiment including:
(0079] (i) Random peptide sequences encoded by syn­
thetic DNA of variable length. 
[0080] (ii) Single-chain Fv antibody fragments. These 
consist of the antibody heavy and light chain variable 
region domains joined by a flexible linker peptide to 
create a single-chain antigen binding molecule. 
[0081] (iii) Random fragments of naturally occurring 
proteins isolated from a cell population containing an 
activity of interest. 
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(0082] In another embodiment the invention concerns 
methods for screening a DNA library whose members require 
more than one chain for activity, as required by, for example, 
antibody Fab fragments for ligand binding. In this embodi­
ment heavy or light chain antibody DNA is joined to a nucle­
otide sequence encoding a DNA binding domain of, for 
example, the oestrogen receptor in a phagemid vector. Typi­
cally the antibody DNA library sequences for either the heavy 
(VH and CHI) or light chain (VL and CL) genes are inserted 
in the 5' region of the oestrogen receptor DBD DNA, behind 
an appropriate promoter and translation sequences and a 
sequence encoding a signal peptide leader directing transport 
of the downstream fusion protein to the periplasmic space. 
(0083] Thus, a DBD fused to a DNA library member-en­
coded protein is produced and assembled in to the viral par­
ticle after infection with bacteriophage. The second and any 
subsequent chain(s) are expressed separately either: 
(a) from the same phagemid vector containing the DBD and
the first polypeptide fusion protein, or
(b) from a separate region of DNA which may be present in
the host cell nucleus, or on a plasmid, phagemid or bacte­
riophage expression vector that can co-exist, in the same host
cell, with the first expression vector, so as to be transported to
the periplasm where they assemble with the first chain that is
fused to the DBD protein as it exits the cell. Peptide display
carrier packages (PDCP) which encode the protein of interest
can then be selected by means of a ligand specific for the
protein.
(0084] In yet another embodiment, the invention concerns
screening libraries of bi-functional peptide display carrier
packages where two or more activities of interest are dis­
played on each PDCP. In this embodiment, a first DNA library
sequence(s) is inserted next to a first DNA binding domain
(DBD) DNA sequence, for example the oestrogen receptor
DBD, in an appropriate vector, behind an appropriate pro­
moter and translation sequences and a sequence encoding a
signal peptide leader directing transport of this first chimeric
protein to the periplasmic space. A second chimeric protein is
also produced from the same, or separate, vector by inserting
a second DNA library sequence(s) next to a second DBD
DNA sequence which is different from the first DBD DNA
sequence, for example the progesterone receptor DBD.
behind an appropriate promoter and translation sequences
and a sequence encoding a signal peptide leader. The first, or
only, vector contains the specific HRE nucleotide sequences
for both oestrogen and progesterone receptors. Expression of
the two chimeric proteins, results in a PDCP with two differ­
ent chimeric proteins displayed. As an example, one chimeric
protein could possess a binding activity for a particular ligand
of interest, while the second chimeric protein could possess
an enzymatic activity. Binding by the PDCP to the ligand of
the first chimeric protein could then be detected by subse­
quent incubation with an appropriate substrate for the second
chimeric protein. In an alternative embodiment a bi-func­
tional PDCP may be created using a single DBD, by cloning
one peptide at the 5'-end of the DBD, and a second peptide at
the 3'-end of the DBD. Expression of this single bi-functional
chimeric protein results in a PDCP with two different activi­
ties.
(0085] We have investigated the possibility of screening
libraries of peptides, fused to a DNA binding domain and
displayed on the surface of a display package, for particular
peptides with a biological activity of interest and recovering
the DNA encoding that activity. Surprisingly, by manipulat-
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ing the oestrogen receptor DNA binding domain in conjunc­
tion with M13 bacteriophage we have been able to constrnct 
novel particles which display large biologically functional 
molecules, that allows enrichment of particles with the 
desired specificity. 
(0086] The invention described herein provides a signifi­
cant breakthrough in DNA library screening technology. 
(0087] The invention will now be further described by ref­
erence to the non-limiting exan1ples and figures below. 
DESCRIPTION OF FIGURES 
(0088] FIG. 1 shows the pDM12 N-terminal fusion oestro­
gen receptor DNA binding domain expression vector nucle­
otide sequence (SEQ ID No 1 ), between the HindIII and 
EcoRI restriction sites, comprising a pe!B leader secretion 
sequence (in italics) (SEQ ID No 2), multiple cloning site 
containing Sfil and Notl sites. flexible (glycine)4-serine 
linker sequence (boxed), a fragment of the oestrogen receptor 
gene comprising amino acids 176-282 (SEQ ID No 3) of the 
full length molecule, and the 38 base pair consensus oestro­
gen receptor DNA binding domain HRE sequence. 
(0089] FIG. 2 shows the OD4sonm ELISA data for negative 
control M13K07 phage, and single-clone PDCP display cul­
ture supernatants (#1-4, see Example 3) isolated by selection 
of the lymphocyte cDNA-pDM12 library against anti-human 
inununoglobulin kappa antibody. 
(0090] FIG. 3 shows partia! DNA (SEQ ID No 4) and amino 
acid (SEQ ID No 5) sequence for the human inununoglobulin 
kappa constant region (Kabat, E. A. et al., Sequences of 
Proteins of lmmunological Interest. 4th edition. U.S. Depart­
ment of Health and Hmnan Services. 1987), and ELISA posi­
tive clones #2 (SEQ ID Nos 6 and 7) and #3 (SEQ ID Nos 8 
and 9) from FIG. 2 which confirms the presence of human 
kappa constant region DNA in-frame with the pe!B leader 
sequence (pe!B leader sequence is underlined. the leader 
sequence cleavage site is indicated by an arrow). The differ­
ences in the 5'-end sequence demonstrates that these two 
clones were selected independently from the library stock. 
The PCR primer sequence is indicated in bold, clone #2 was 
originally amplified with CDNAPCRBAKl and clone #3 was 
amplified with CDNAPCRBAK2. 
(0091] FIG. 4 shows the pDM14 N-terminal fusion oestro­
gen receptor DNA binding domain expression vector nucle­
otide sequence (SEQ ID No 10). between the HindIII and 
EcoRI restriction sites, comprising a pe!B leader secretion 
sequence (in italics) (SEQ ID No 11), multiple cloning site 
containing Sfil and Notl sites, flexible (glycine)4-serine 
linker sequence (boxed), a fragment of the oestrogen receptor 
gene comprising amino acids 176-282 (see SEQ ID No 12) of 
the full length molecule, and the two 38 base pair oestrogen 
receptor DNA binding domain HRE sequences (HRE 1 and 
HRE 2). 
(0092] FIG. 5 shows the pDMl 6 C-terminal fusion oestro­
gen receptor DNA binding domain expression vector nucle­
otide sequence (SEQ ID No 13), between the HindIII and 
EcoRI restriction sites, comprising a pe!B leader secretion 
sequence (in italics), a fragment of the oestrogen receptor 
gene comprising amino acids 176-282 (SEQ ID No 14) of the 
full length molecule, flexible (glycine kserine linker 
sequence (boxed), multiple cloning site containing Sfil and 
Notl sites and the 38 base pair oestrogen receptor DNA bind­
ing domain HRE sequence. 
(0093] FIG. 6 shows the OD4sonm ELISA data for N-cad­
herin-pDMl 6 C-terminal display PDCP binding to anti-pan-
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cadherin monoclonal antibody in serial dilution ELISA as 
ampicillin resistance units (a.r.u.). Background binding of 
negative control M13K07 helper phage is also shown. 
[0094] FIG. 7 shows the OD45011m ELISA data for in vivo 
biotinylated PCC-pDMl 6 C-terminal display PDCP binding 
to streptavidin in serial dilution ELISA as ampicillin resis­
tance units (a.r.u.). Background binding of negative control 
M13K07 helper phage is also shown. 
[ 0095] FIG. 8 shows the OD 450 nm ELISA data for a human 
scFv PDCP isolated from a human scFv PDCP display library 
selected against substance P. The PDCP was tested against 
streptavidin (1 ), streptavidin-biotinylated substance P (2), 
and streptavidin-biotinylated CGRP (3), in the presence (B) 
or absence (A) of free substance P. 
[0096] FIG. 9 shows the DNA (SEQ ID Nos 15 and 17) and 
amino acid (SEQ ID No 16 and 18) sequence of the substance 
P binding scFv isolated from a human scFv PDCP display 
library selected against substance P. Heavy chain (SEQ ID 
Nos 15 and 16) and light chain (SEQ ID Nos 17 and 18) 
variable region sequence is shown with the CDRs underlined 
and highlighted in bold. 
MATERIALS AND METHODS 
[0097] The following procedures used by the present appli­
cant are described in Sambrook, J., et al., 1989 supra.: restric­
tion enzyme digestion, ligation, preparation of electrocom­
petent cells, electroporation, analysis of restriction enzyme 
digestion products on agarose gels, DNA purification using 
phenol/chloroform, preparation of 2xTY medium and plates, 
preparation of ampicillin, kanamycin, IPTG (Isopropyl �-D­
Thiogalactopyranoside) stock solutions, and preparation of 
phosphate buffered saline. 
[0098] Restriction enzymes, T4 DNA ligase and cDNA 
synthesis reagents (Superscript plasmid cDNA synthesis kit) 
were purchased from Life Technologies Ltd (Paisley, Scot­
land, U.K.). Oligonucleotides were obtained from Cruachem 
Ltd (Glasgow, Scotland, U.K.), or Genosys Bioteclmologies 
Ltd (Cambridge, U.K.). Taq DNA polymerase, Wizard SV 
plasmid DNA isolation kits, streptavidin coated magnetic 
beads and mRNA isolation reagents (PolyATract 1 OOO) were 
obtained from Promega Ltd (Southampton, Hampshire, 
U.K.). Taqplus DNA polymerase was obtained from Strat­
agene Ltd (Cambridge, U.K.). PBS, BSA, streptavidin, sub­
stance P and anti-pan cadherin antibody were obtained from
SIGMA Ltd (Poole, Dorset, U.K.). Anti-M13-HRP conju­
gated antibody, Kanamycin resistant M13K07 helper bacte­
riophage and RNAguard were obtained from Pharmacia Ltd
(St. Albans, Herts, U.K.) and anti-human IgK antibody from
Harlan-Seralab (Loughborough, Leicestershire, U.K.) Bioti­
nylated substance P and biotinylated calcitonin gene related
peptide (CGRP) were obtained from Peninsula Laboratories
(St. Helens, Merseyside, U.K.).
[0099] Specific embodiments of the invention are given
below in Examples 1 to 9.
EXAMPLE 1 
Construction of a N-Tem1inal PDCP Display 
Phagemid Vector pDM12 
[0100] The pDM12 vector was constructed by inserting an 
oestrogen receptor DNA binding domain, modified by appro­
priate PCR primers, into a phagemid vector pDM6. The 
pDM6 vector is based on the pUC119 derived phage display 
vector pHENl (Hoogenboom et al., 1991, Nucleic Acids Res. 
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19: 4133-4137). It contains (Gly)4Ser linker, Factor Xa cleav­
age site, a foll length gene III, and streptavidin tag peptide 
sequence (Schmidt, T. G. and Skerra, A., 1993, Protein Engi­
neering 6: 109-122), all of which can be removed by NotI­
EcoRI digestion and agarose gel electrophoresis, leaving a 
pe!B leader sequence, Sfil, Ncol and Pstl restriction sites 
upstream of the digested Notl site. The cloned DNA binding 
domain is under the control of the lac promoter found in 
pUC119. 
Preparation of pDM6 
[0101] The pDM12 vector was constructed by inserting an 
oestrogen receptor DNA binding domain, modified by appro­
priate PCR primers, into a phagemid vector pDM6. The 
pDM6 vector is based on the gene pIII phage display vector 
pHENl (Hoogenboom et al., 1991, Nucleic Acids Res. 19: 
4133-4137), itself derived from pUCl 19 (Viera, J. and Mess­
ing, J., 1987, Methods in Enzymol. 153: 3-11). It was con­
structed by amplifying the pIII gene in pHENl with two 
oligonucleotides: 
(SEQ ID No 19) 
PDM6BAK: 
5 -TTT TCT GCA GTA ATA GGC GGC CGC AGG GGG AGG AGG 
GTC CAT CGA AGG TCG CGA AGC AGA GAC TGT TGA AAG T-
3 
and 
(SEQ ID No 20) 
PDM6FOR: 
5 -TTT TGA ATT CTT ATT AAC CAC CGA ACT GCG GGT GAC 
GCC AAG CGC TTG CGG CCG TTA AGA CTC CTT ATT ACG 
CAG-3. 
and cloning the PstI-EcoRI digested PCR product back into 
similarly digested pHENl ,  thereby removing the c-myc tag 
sequence and supE TAG codon from pHENl .  The pDM6 
vector contains a (Gly)4Ser linker, Factor Xa cleavage site, a 
foll length gene III, and streptavidin tag peptide sequence 
(Schmidt, T. G. and Skerra, A., 1993, Protein Engineering 6: 
109-122), all of which can be removed by NotI-EcoRI diges­
tion and agarose gel electrophoresis, leaving a pe!B leader
sequence, SfiI, NcoI and Pstl restriction sites upstream of the
digested Notl site. The cloned DNA binding domain is under
the control of the lac promoter found in pUCl 19.
[0102] The oestrogen receptor DNA binding domain was 
isolated from cDNA prepared from human bone marrow 
(Clontech, Palo Alto, Calif., U.S.A.). cDNA can be prepared 
by many procedures well known to those skilled in the art. As 
an example, the following method using a Superscript plas­
mid cDNA synthesis kit can be used: 
(a) First Strand Synthesis.
[0103] 5 µg of bone marrow mRNA, in 5 �t! DEPC-treated 
water was thawed on ice and 2 µl ( 50 pmol) of cDNA synthe­
sis primer (5'-AAAAGCGGCCGCACTGGCCTGAGAGA 
(N)6-3') (SEQ ID No 21) was added to the mRNA and the 
mixture heated to 70° C. for 10 minutes, then snap-chilled on 
ice and spun briefly to collect the contents to the bottom of the 
tube. The following were then added to the tube: 
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1000 u/ml RNAguard 1 µl 
5x first strand buffer 4 µl 
O.lMDTT 2 µl 
10 mM dNTPs 1 µl 
200 u/µl Superscript II reverse transcriptase 5 µl 
The mixture was mixed by pipetting gently and incubated at 
37° C. for 1 hour, then placed on ice. 
(b) Second Strand Synthesis.
[0104] The following reagents were added to the first strand 
reaction: 
DEPC-treated water 93 µl 
5x second strand buffer 30 µl 
10 mM dNTPs 3 µl 
10 uiµl E. coli DNA ligase 1 µl 
10 coli DNA polymerase 4 µl 
2 coli RNase H 1 µl 
[0105] The reaction was vortex mixed and incubated at 16° 
C. for 2 hours. 2 µI (lOu) ofT4 DNA polymerase was added
and incubation continued at 16° C. for 5 minutes. The reaction
was placed on ice and 10 µ1 0.5M EDTA added, then phenol­
chloroform extracted, precipitated and vacuum dried.
( c) Sal I Adaptor Ligation.
[0106] The cDNA pellet was resuspended in 25 µI DEPC­
treated water, and ligation set up as follows. 
cDNA 
5x T4 DNA ligase buffer 
1 µg/µl Sal I adapters* 
1 u/µ1T4 DNA ligase 
*Sal I adapters: 
TCGACCCACGCGTCCG-3' 
GGGTGCCGAGGC-5' 
25 µl 
10 µl 
10 µl 
5 µl 
(SEQ ID No 22) 
(SEQ ID No 23) 
[0107] The ligation was mixed gently and incubated for 16 
hours at 16° C., then phenol-chloroform extracted, precipi­
tated and vacuum dried. The cDNA/adaptor pellet was resus­
pended in 41 µI ofDEPC-treated water and digested with 60 
units ofNotI at 37° C. for 2 hours, then phenol-chloroform 
extracted, precipitated and vacuum dried. The cDNA pellet 
was re-dissolved in 100 �tl TEN buffer (10 mM Iris pH 7.5, 
0.1 mM EDD\., 25 mM NaCl) and size fractionated using a 
Sephacryl S-500 HR colmnn to remove llllligated adapters 
and small cDNA fragments ( <400 bp) according to the manu­
facturers instructions. Fractions were checked by agarose gel 
electrophoresis and fractions containing cDNA less than 400 
base pairs discarded, while the remaining fractions were 
pooled. 
( d) PCR Amplification of Oestrogen Receptor DNA Binding
Domain.
[0108] The oestrogen receptor was PCR amplified from 5 
µI (150-250 ng) of bone marrow cDNA using 25 pmol of each 
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of the primers pDM12FOR (SEQ ID No 24) (5'-AAAA­
GAATTCTGAATGTGTTATTTI�GCTCAG­
GTCACTCTGACCTGATI�TCAAGAC­
CCCACTTCACCCCCT) and pDM12BAK (SEQ ID No 25) 
(5'-AAAAGCGGCCGCAGGGGGAGGAGGGTC­
CATGGAATCTGCCAAGGAG-3') in two 50 µI reactions 
containing 0.1 mM dNTPs, 2.5 units Taq DNA polymerase, 
and l xPCR reaction buffer (10 mM Tris-HCI pH 9.0, 5 mM 
KC!, 0.01 % Triton XrID-100, 1.5 mM MgCl2) (Promega Ltd, 
Southampton, U.K.). The pDM12FOR primer anneals to the 
3'-end of the DNA binding domain of the oestrogen receptor 
and incorporates two stop codons, the 38 base pair consensus 
oestrogen receptor HRE sequence, and an EcoRI restriction 
site. The pDM12BAK primer anneals to the 5'-end of the 
DNA binding domain of the oestrogen receptor and incorpo­
rates the (Gly)4Ser linker and the NotI restriction site. 
[0109] Reactions were overlaid with mineral oil and PCR 
carried out on a Teclme PHC-3 thermal cycler for 30 cycles of 
94° C., 1 minute; 65° C., 1 minute; 72° C., 1 minute. Reaction 
products were electrophoresed on an agarose gel, excised and 
products purified from the gel using a Geneclean II kit accord­
ing to the manufacturers instructions (BiolOl, La Jolla, 
Calif., U.S.A.). 
( e) Restriction Digestion and Ligation.
[011 OJ The PCR reaction appended Notl and EcoRI restric­
tion sites, the (Gly)4Ser linker, stop codons and the 38 base 
pair oestrogen receptor target HRE nucleotide sequence to 
the oestrogen receptor DNA binding domain sequence (see 
FIG. l). The DNA PCRfragment and the target pDM6 vector 
(approximately 500 ng) were Notl and EcoRI digested for 1 
hour at 3 7° C., and DNA purified by agarose gel electrophore­
sis and extraction with Geneclean II kit (Bio 101, La Jolla, 
Calif., U.S.A.). The oestrogen receptor DNA binding domain 
cassette was ligated into the NotI-EcoRI digested pDM6 vec­
tor overnight at 16° C., phenol/chloroform extracted and pre­
cipitated then electroporated into TG 1 E. coli (genotype: 
Kl2, (Iliac-pro), supE, tin, hsD5/F'traD36, proA+w, Laclq, 
LacZLl15) and plated onto 2xTY agar plates supplemented 
with 1 % glucose and 100 µ g/ml ampicillin. Colonies were 
allowed to grow overnight at 37° C. Individual colonies were 
picked into 5 ml 2xTY supplemented with 1 % glucose and 
100 �tg/ml ampicillin and grown overnight at 37° C. Double 
stranded phagemid DNA was isolated with a Wizard SV 
plasmid DNA isolation kit and the sequence confirmed with a 
Prism dyedeoxy cycle sequencing kit (Perkin-Elmer, War­
rington, Lancashire, U.K.) using M13FOR (SEQ ID No 26) 
(5'-GTAAAACGACGGCCAGT) and M13REV (SEQ ID No 
27) (5'-GGATAACAATTTCACACAGG) oligonucleotides.
The pDM12 PDCP display vector DNA sequence between
the HindIII and EcoRI restriction sites is shown in FIG. 1.
EXAMPLE 2 
Insertion of a Random-Primed Human Lymphocyte 
cDNA into pDM12 and Preparation of a Master 
PDCP Stock 
[0111] Libraries of peptides can be constructed by many 
methods known to those skilled in the art. The example given 
describes a method for constructing a peptide library from 
randomly primed cDNA, prepared from mRNA isolated from 
a partially purified cell population. 
[0112] mRNA was isolated from approximately 109 human 
peripheral blood lymphocytes using a poly ATract 1 OOO 
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mRNA isolation kit (Promega, Southampton, UK). The cell 
pellet was resuspended in 4 ml extraction buffer (4M guani­
dine thiocyanate, 25 mM sodium citrate pH 7.1, 2% P-mer­
captoethanol). 8 ml of pre-heated (70° c.) dilution buffer 
(6xSSC, 10 mM Iris pH 7.4, 1 mM EDTA, 0.25% SDS, 1 % 
P-mercaptoethanol) was added to the homogenate and mixed
thoroughly by inversion. 10 µl of biotinylated oligo-dT ( 50
pmol/µl) was added, mixed and the mixture incubated at 70° 
C. for 5 minutes. The lymphocyte cell lysate was transferred
to 6x2 ml sterile tubes and spun at 13,000 rpm in a microcen­
trifuge for ten minutes at ambient temperature to produce a
cleared lysate. During this centrifugation, streptavidin coated
magnetic beads were resuspended and 6 ml transferred to a
sterile 50 ml Falcon tube, then placed in the magnetic stand in
a horizontal position until all the beads were captured. The
supernatant was carefully poured off and beads resuspended
in 6 ml 0.5xSSC, then the capture repeated. This wash was
repeated 3 times, and beads resuspended in a final volume of
6 ml 0.5xSSC. The cleared lysate was added to the washed
beads, mixed by inversion and incubated at ambient tempera­
ture for 2 minutes, then beads captured in the magnetic stand
in a horizontal position. The beads were resuspended gently
in 2 ml 0.5xSSC and transferred to a sterile 2 ml screwtop
tube, then captured again in the vertical position, and the wash
solution discarded. This wash was repeated twice more. 1 ml 
of DEPC-treated water was added to the beads and mixed
gently. The beads were again captured and the eluted mRNA
transferred to a sterile tube. 501 was electrophoresed to check
the quality and quantity of mRNA, while the remainder was
precipitated with 0.1 volumes 3M sodium acetate and three
volumes absolute ethanol at -80° C. overnight in 4 aliquots in
sterile 1.5 ml screwtop tubes.
(0113] Double stranded cDNA was synthesised as
described in Example 1 using 5 µg of lymphocyte mRNA as
template. The cDNA was PCR amplified using oligonucle­
otides CDNAPCRFOR (SEQ ID No 28) (5'-AAAGCGGC­
CGCACTGGCCTGAGAGA), which anneals to the cDNA
synthesis oligonucleotide described in Example 1 which is
present at the 3'-end of all synthesised cDNA molecules
incorporates a Notl restriction site, and an equimolar mixture
of CDNAPCRBAKl ,  CDNAPCRBAK2 and CDNAPCR­
BAK3. CDNAPCRBAKl: (SEQ ID No 29) 5'-AAAAGGC­
CCAGCCGGCCATGGCCCAGCCCACCACGCGTCCG,
CDNAPCRBAK2: (SEQ ID No 30) 5'-AAAAGGCCCAGC­
CGGCCATGGCCCAGTCCCACCACGCGTCCG,
CDNAPCRBAK3: (SEQ ID No 31) 5'-AAAAGGCCCAGC­
CGGCCATGGCCCAGTACCCACCACGCGTCCG), all
three of which anneal to the Sall adaptor sequence found at
the 5'-end of the cDNA and incorporate a SfiI restriction site
at the cDNA 5'-end. Ten PCR reactions were carried out using
2 µl of cDNA (50 ng) per reaction as described in Example 1
using 25 cycles of 94° C., 1 minute; 60° C., 1 minute; 72° C.,
2 minutes. The reactions were pooled and a 20 µl aliquot
checked by agarose gel electrophoresis, the remainder was
phenol/chloroform extracted and ethanol precipitated and
resuspended in 100 µl sterile water. 5 µg of pDM12 vector
DNA and lymphocyte cDNA PCR product were SfiI-NotI
digested phenol/chloroform extracted and small DNA frag­
ments removed by size selection on Chromaspin 1 OOO spin
columns (Clontech, Palo Alto, Calif., U.S.A.) by centrifuga­
tion at 700 g for 2 minutes at room temperature. Digested
pDM12 and lymphocyte cDNA were ethanol precipitated and
ligated together for 16 hours at 16° C. The ligated DNA was
precipitated and electroporated in to TG 1 E. coli. Cells were
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grown in 1 ml SOC medium per cuvette used for 1 hour at 37° 
C., and plated onto 2xTY agar plates supplemented with 1 % 
glucose and 100 µg/ml ampicillin. 10-4, 10-5 and 10-6 dilu­
tions of the electroporated bacteria were also plated to assess 
library size. Colonies were allowed to grow overnight at 30° 
C. 2xl 08 ampicillin resistant colonies were recovered on the
agar plates.
[0114] The bacteria were then scraped off the plates into 40
ml 2xTY broth supplemented with 20% glycerol, 1 % glucose
and 100 µg/ml ampicillin. 5 ml was added to a 20 ml 2xTY
culture broth supplemented with 1 % glucose and 100 µg/ml
ampicillin and infected with 1011 kanamycin resistance units
(kru) MI3K07 helper phage at 37° C. for 30 minutes without
shaking, then for 30 minutes with shaking at 200 rpm.
Infected bacteria were transferred to 200 ml 2xTY broth
supplemented with 25 µg/ml kanamycin, 100 µg/ml ampicil­
lin, and 20 µM IPTG, then incubated overnight at 37° C.,
shaking at 200 rpm. Bacteria were pelleted at 4000 rpm for 20 
minutes in 50 ml Falcon tubes, and 40 ml 2.5M NaCl/20%
PEG 6000 was added to 200 ml of particle supernatant, mixed
vigorously and incubated on ice for 1 hour to precipitate
PDCP particles. Particles were pelleted at 11 OOO rpm for 30
minutes in 250 ml Oakridge tubes at 4 ° C. in a Sorvall RC5B
centrifuge, then resuspended in 2 ml PBS buffer after remov­
ing all traces of PEG/NaCl with a pipette, then bacterial
debris removed by a 5 minute 13500 rpm spin in a microcen­
trifuge. The supernatent was filtered through a 0.45 rim
polysulfone syringe filter and stored at -20° C.
EXAMPLE 3 
Isolation of Human Immunoglobulin Kappa Light 
Chains by Repeated Rounds of Selection Against 
Anti-Human Kappa Antibody 
[0115] For the first round of library selection a 70x 11 mm 
NUNC Maxisorp Immunotube (Life Technologies, Paisley, 
Scotland U.K.) was coated with 2.5 ml of 10 ftg/ml of anti­
hunian kappa antibody (Seralab, Crawley Down, Sussex, 
U.K.) in PBS for 2 hours at 37° C. The tube was rinsed three
times withPBS (fill & empty) and blocked with 3 ml PBS/2%
BSA for 2 hours at 37° C. and washed as before. 4x l 012 a.r.u.
of pDM12-lymphocyte cDNA PDCP stock was added in 2 ml
2% BSA/PBS/0.05% Tween 20, and incubated for 30 minutes
on a blood mixer, then for 90 minutes standing at an1bient
temperature. The tube was washed ten times with PBS/0.1 %
Tween 20, then a further ten times with PBS only. Bound
particles were eluted in 1 ml of freshly prepared 0.1 M triethy­
lamine for 10 minutes at ambient temperature on a blood
mixer. Eluted particles were transferred to 0.5 ml IM Iris pH
7.4, vortex mixed briefly and transferred to ice.
[0116] Neutralised particles were added to 10 ml log phase
TGI E coli bacteria (optical density: OD600 nm 0.3-0.5) and
incubated at 3 7° C. without shaking for 30 minutes, then with
shaking at 200 rpm for 30 minutes. 10-3, 10-4 & 10-5 dilu­
tions of the infected culture were prepared to estimate the
nnmber of particles recovered, and the remainder was spun at
4000 rpm for 10 minutes, and the pellet resuspended in 300 rt!
2xTY medium by vortex mixing. Bacteria were plated onto
2xTY agar plates supplemented with 1 % glucose and 100
µg/ml ampicillin. Colonies were allowed to grow overnight at
30° C.
[0117] A PDCP stock was prepared from the bacteria
recovered from the first round of selection, as described in
Example 2 from a 100 ml overnight culture. 250 µl of the
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round 1 amplified PDCP stock was then selected against 
anti-human kappa antibody as described above with the tube 
was washed twelve times with PBS/0.1 % Tween 20, then a 
further twelve times with PBS only. 
(0118] To identify selected clones, eighty-eight individual 
clones recovered from the second round of selection were 
then tested by ELISA for binding to anti-human kappa anti­
body. Individual colonies were picked into 100 µI 2xTY 
supplemented with 100 µg/ml ampicillin and 1 % glucose in 
96-well plates (Costar) and incubated at 37° C. and shaken at
200 rpm for 4 hours. 25 �LI of each culture was transferred to
a fresh 96-well plate, containing 25 µI/well of the same
medium plus 10 7 k.r.u. M l  3K07 kanamycin resistant helper
phage and incubated at 37° C. for 30 minutes without shak­
ing, then incubated at 37° C. and shaken at 200 rpm for a
further 30 minutes. 160 µI of 2xTY supplemented with 100
µg/ml ampicillin, 25 µg/ml kanamycin, and 20 �tM IPTG was
added to each well and particle amplification continued for 16
hours at 37° C. while shaking at 200 rpm. Bacterial cultures
were spun in microtitre plate carriers at 2000 g for 10 minutes
at 4 ° C. in a benchtop centrifuge to pellet bacteria and culture
supernatant used for ELISA.
(0119] A Dynatech Immulon 4 ELISA plate was coated
with 200 ng/well anti-human kappa antibody in 100 µI/well
PBS for one hour at 37° C. The plate was washed 2x200
�t!/well PBS and blocked for 1 hour at 3 7° C. with 200 µI/well
2% BSA/PBS and then washed 2x200 �tl/well PBS. 50 �tl
PDCP culture supernatant was added to each well containing
50 �Ll/well 4% BSA/PBS/0.l % Tween 20, and allowed to bind
for 1 hour at ambient temperature. The plate was washed three
times with 200 µI/well PBS/0.l % Tween 20, then three times
with 200 µI/well PBS. Bound PDCPs were detected with 100
�t!/well, 1 :5000 diluted anti-M13-HRP conjugate (Pharma­
cia) in 2% BSA/PBS/0.05% Tween 20 for 1 hour at ambient
temperature and the plate washed six times as above. The
plate was developed for 5 minutes at ambient temperature
with 100 µI/well freshly prepared TMB (3,3',5,5'-Tetrameth­
ylbenzidine) substrate buffer (0.005% H202, 0.1 mg/ml TMB 
in 24 mM citric acid/52 mM sodium phosphate buffer pH 
5.2). The reaction was stopped with 100 µl/well 12.5% H2S04 
and read at 450 nm. (ELISA data for binding clones is shown 
in FIG. 2). These clones were then sequenced with M13REV 
primer (SEQ ID No 27) as in Example 1. The sequence of two 
of the clones isolated is shown in FIG. 3 (see SEQ ID Nos 7 
to 10). 
EXAMPLE 4 
Construction of the pDM14 N-Terminal Display 
Vector 
(0120] It would be useful to design vectors that contain a 
second DBD binding sequence, such as a second oestrogen 
receptor HRE sequence, thus allowing the display of 
increased numbers of peptides per PDCP. Peale et al. (1988, 
Proc. Natl. Acad. Sci. USA 85: 1038-1042) describe a num­
ber of oestrogen receptor HRE sequences. These sequences 
were used to define an HRE sequence, which differs from that 
cloned in pDM12. which we used to create a second N-ter­
minal display vector (pDM14). The oligonucleotide: 
5'-AAAAGA.L\.TTCGAGGTTACAT­
TAACTTTGTTCCGGTCAGACTGAC­
CCAAGTCGACCTGAATGTGTTATTTTAG-3, (SEQ ID 
No 32) was synthesised and used to mutagenise pDM12 by 
PCR with pDM12BAK oligonucleotide as described in 
10 
Sep. 11, 2008 
Example 1 using 100 ng pDM12 vector DNA as template. 
The resulting DNA fragment, which contained the oestrogen 
receptor DBD and two HRE sequences separated by a Sall 
restriction enzyme site, was NotI-EcoRI restriction enzyme 
digested and cloned into NotI-EcoRI digested pDM12 vector 
DNA as described in Example 1 to create pDM14. The 
sequence of pDMl 4 between the HindIII and EcoRI restric­
tion enzyme sites was checked by DNA sequencing. The final 
vector sequence between these two sites is shown in FIG. 4 
(see SEQ ID Nos 11 and 12). 
EXAMPLE 5 
Construction of the pDMl 6 C-Terminal Display Vec­
tor 
(0121] In order to demonstrate the display of peptides fused 
to the C-terminus of a DBD on a PDCP a suitable vector, 
pDM16, was created. 
(0122] In pDM16 the pe!B leader DNA sequence is fused 
directly to the oestrogen receptor DBD sequence removing 
the multiple cloning sites and the Gly 4Ser linker DNA 
sequence found in pDM12 and pDM14, which are appended 
to the C-terminal end of the DBD sequence upstream of the 
HRE DNA sequence. 
(0123] To create this vector two separate PCR reactions 
were carried out on a Techne Progene thermal cycler for 30 
cycles of94° C., 1 minute; 60° C., 1 minute; 72° C., 1 minute.
Reaction products were electrophoresed on an agarose gel, 
excised and products purified from the gel using a Mermaid or 
Geneclean II kit, respectively, according to the manufacturers 
instructions (Bio 101, La Jolla, Calif., U.S.A.). 
(0124] In the first, the 5'-untranslated region and pe!B 
leader DNA sequence was amplified from 100 ng of pDM12 
vector DNA using 50 pmol of each of the oligonucleotides 
pe!BFOR (SEQ ID No 33) (5'-CCTTGGCAGATTC­
CATCTCGGCCATTGCCGGC-3') and M13REV (SEQ ID 
NO 27) (see above) in a 100 µI reaction containing 0.1 mM 
dNTPs, 2.5 units Taqplus DNA polymerase, and 1 x High Salt 
PCR reaction buffer (20 mM Tris-HCI pH 9 .2, 60 mM KC!, 2 
mM MgCl2) (Stratagene Ltd, Cambridge, U.K.). 
(0125] In the second, the 3'-end of the pe!B leader sequence 
and the oestrogen receptor DBD was amplified from 100 ng 
of pDM12 vector DNA using 50 pmol of each of the oligo­
nucleotides pe!BBAK (SEQ ID No 34) (5'-CCGGCAATG­
GCCGAGATGGAATCTGCCA.L\.GG-3') and pDM16FOR 
(SEQ ID No 35) (5'-TTITGTCGACTCAATCAGTIAT­
GCGGCCGCCAGCTGCAGGAGGGCCG­
GCTGGGCCGACCCTCCTCCCCCAGAC­
CCCACTTCACCCC-3') in a 100 �LI reaction containing 0.1 
mM dNTPs, 2.5 units Taqplus DNA polymerase, and lx High 
Salt PCR reaction buffer (Stratagene Ltd, Cambridge, U.K.). 
Following gel purification both products were mixed together 
and a final round of PCR amplification carried out to link the 
two products together as described above, in a 100 �LI reaction 
containing 0.1 mM dNTPs, 2.5 units Taq DNA polymerase, 
and 1 xPCR reaction buffer (10 mM Tris-HCI pH 9 .0, 5 mM 
KC!, 0.01 % Triton X®-100, 1.5 mM MgCl2) (Promega Ltd, 
Southampton, U.K.). 
(0126] The resulting DNA fragment, was HindIII-Sa!I 
restriction enzyme digested and cloned into HindIII-Sa!I 
digested pDM14 vector DNA as described in Example 1 to 
create pDMl 6. The sequence of pDMl 6 between the HindIII 
and EcoRI restriction enzyme sites was checked by DNA 
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sequencing. The final vector sequence between these two 
sites is shown in FIG. 5 (see SEQ ID Nos 13 and 14). 
EXAMPLE 6 
Display of the C-Tenninal Fragment of Human 
N-Cadherin on the Surface of a PDCP
(0127] cDNA libraries of peptides can be constructed by 
many methods known to those skilled in the art. One com­
monly used method for constructing a peptide library uses 
oligo dT primed cDNA, prepared from polyA+ mRNA. In 
this method the first-strand synthesis is carried out using an 
oligonucleotide which anneals to the 3'-end polyA tail of the 
mRNA composed ofT,., ( where n is nonnally between 10 and 
20 bases) and a restriction enzyme site such as Notl to facili­
tate cloning of cDNA. The cDNA cloned by this method is 
nonnally composed of the poly A tail, the 3'-end untranslated 
region and the C-tern1inal coding region of the protein. As an 
example of the C-tern1inal display of peptides on a PDCP, a 
human cDNA isolated from a library constructed by the above 
method was chosen. 
(0128] The protein N-cadherin is a cell surface molecule 
involved in cell-cell adhesion. The C-terminal cytoplasmic 
domain of the human protein (Genbank database accession 
number: M34064) is recognised by a commercially available 
monoclonal antibody which was raised against the C-tenni­
nal 23 amino acids of chicken N-cadherin (SIGMA catalogue 
number: C-1821). The l.4 kb human cDNA fragment encod­
ing the C-tern1inal 99 amino acids, 3'-untranslated region and 
polyA tail (Notl site present at the 3'-end of the poly A tail) 
was amplified from approximately 20 ng pDM7-NCAD#C 
with 25 pmol of each oligonucleotide M13FOR (SEQ ID No 
26) and CDNPCRBAKl (SEQ ID No 29) (see above) in a 501
reaction containing 0.1 mM dNTPs, 2.5 units Taqplus DNA
polymerase, and 1 x High Salt PCR reaction buffer (20 mM
Tris-HCI pH 9 .2, 60 mM KC!, 2 mM MgCl2) (Strata gene Ltd,
Cambridge, U.K.) on a Techne Progene thermal cycler for 30
cycles of94° C., 1 minute; 60° C., 1 minute; 72° C., 1 minute.
Following gel purification and digestion with SfiI and Notl
restriction enzymes, the PCR product was cloned into
pDMI 6 using an analogous protocol as described in Example
1.
[0129] Clones containing inserts were identified by ELISA
of 96 individual PDCP cultures prepared as described in
Example 3. A Dynatech Immulon 4 ELISA plate was coated
with 1 :250 diluted anti-pan cadherin monoclonal antibody in
100 µI/well PBS overnight at 4 ° C. The plate was washed
3x200 µI/well PBS and blocked for 1 hour at 37° C. with 200
µI/well 2% Marvel non-fat milk powder/PBS and then
washed 2x200 �t!/well PBS. 50 µI PDCP culture supernatant
was added to each well containing 50 µI/well 4% Marvel/
PBS, and allowed to bind for 1 hour at ambient temperature.
The plate was washed three times with 200 µI/well PBS/0.1 %
Tween 20, then three times with 200 µI/well PBS. Bound
PDCPs were detected with 100 �t!/well, 1:5000 diluted anti­
M13-HRP conjugate (Pharmacia) in 2% Marvel/PBS for 1
hour at ambient temperature and the plate washed six times as
above. The plate was developed for 15 minutes at ambient
temperature with 100 µI/well freshly prepared TMB (3,3',5,
5'-Tetramethylbenzidine) substrate buffer (0.005% H202, 0.1
mg/ml TMB in 24 mM citric acid/52 mM sodium phosphate
buffer pH 5.2). The reaction was stopped with 100 µI/well
12.5%H2S04 and readat 450 nm. The nucleotide sequence of
an ELISA positive clone insert and DBD junction was
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checked by DNA sequencing using oligonucleotides 
M13FOR (SEQ ID No 26) (see Example 1) and ORSEQBAK 
(SEQ ID No 36) (5'-TGTTGAAACACA.L\.GCGCCAG-3'). 
(0130] A fifty-fold concentrated stock of C-terminal 
N-cadherin PDCP particles was prepared by growing the
un-infected TG l clone in l ml 2xTY culture broth supple­
mented with 1 % glucose and 100 g/ml ampicillin for five
hours at 37° C., shaking at 200 rpm and infecting with 108
kanamycin resistance units (kru) M13K07 helper phage at
37° C. for 30 minutes without shaking, then for 30 minutes
with shaking at 200 rpm. Infected bacteria were transferred to
20 ml 2xTY broth supplemented with 25 �tg/ml kanan1ycin,
100 g/ml ampicillin, and 20 µM IPTG, then incubated over­
night at 30° C., shaking at 200 rpm. Bacteria were pelleted at
4000 rpm for 20 minutes in 50 ml Falcon tubes, and 4 ml 2.5M
NaCl/20% PEG 6000 was added to 20 ml of PDCP superna­
tant, mixed vigorously and incubated on ice for 1 hour to
precipitate particles.
(0131] The particles were pelleted at 11000 rpm for 30
minutes in 50 ml Oakridge tubes at 4 ° C. in a Sorvall RC5B
centrifuge, then resuspended in PBS buffer after removing all
traces of PEG/NaCl with a pipette, then bacterial debris
removed by a 5 minute 13500 rpm spin in a microcentrifuge.
The supernatant was filtered through a 0.45 �m1 polysulfone
syringe filter. The concentrated stock was two-fold serially
diluted and used in ELISA against plates coated with anti­
pan-cadherin antibody as described above (see FIG. 6).
(0132] This example demonstrates the principle of C-ter­
minal display using PDCPs, that C-terminal DBD-peptide
fusion PDCPs can be made which can be detected in ELISA,
and the possibility that oligo dT primed cDNA libraries may
be displayed using this method.
EXAMPLE 7 
Display ofln Vivo Biotinylated C-Tenninal Domain 
of Human Propionyl CoA Carboxylase on the Sur-
face of a PDCP 
(0133] Example 6 shows that the C-tern1inal domain of 
human N-cadherin can be expressed on the surface of a PDCP 
as a C-tenninal fusion with the DBD. Here it is shown that the 
C-terminal domain of another human protein propionyl CoA
carboxylase alpha chain (Genbank accession number:
Xl4608) can similarly be displayed, suggesting that this
methodology may be general.
[0134] The alpha sub-unit of propionyl CoA carboxylase
alpha chain (PCC) contains 703 amino acids and is normally
biotinylated at position 669. It is demonstrated that the PCC
peptide displayed on the PDCP is biotinylated, as has been
shown to occur when the protein is expressed in bacterial cells
(Leon-Del-Rio & Gravel; 1994, J. Biol. Chem. 37, 22964-
22968).
[0135] The 0.8 kb human cDNA fragment of PCC alpha
encoding the C-tenninal 95 amino acids, 3'-untranslated
region and poly A tail (Notl site present at the 3'-end of the
polyA tail) was amplified and cloned into pDM16 from
approximately 20 ng pDM7-PCC#C with 25 pmol of each
oligonucleotide M13FOR (SEQ ID No 26) and CDNPCR­
BAKl (SEQ ID No 29) as described in Example 6.
(0136] Clones containing inserts were identified by ELISA
as described in Example 6, except that streptavidin was
coated onto the ELISA plate at 250 ng/well, in place of the
anti-cadherin antibody. The nucleotide sequence of an ELISA
positive clone insert and DBD junction was checked by DNA
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sequencing using oligonucleotides M13FOR (SEQ ID No 26) 
and ORSEQBAK (SEQ ID No 36) (see above). A fifty-fold 
concentrated stock of C-tenninal PCC PDCP particles was 
prepared and tested in ELISA against streptavidin as 
described in Example 6 (see FIG. 7). 
[0137] This example shows not only that the peptide can be 
displayed as a C-tem1inal fusion on a PDCP, but also that in 
viva modified peptides can be displayed. 
EXAMPLES 
Constmction of a Human scFv PDCP Display 
Library 
[0138] This example describes the generation of a human 
antibody library of scFvs made from an un-immunised 
human. The overall strategy for the PCR assembly of scFv 
fragments is similar to that employed by Marks, J. D. et al. 
1991, J. Mo!. Biol. 222: 581-597. The antibody gene oligo­
nucleotides used to constmct the library are derived from the 
Marke et al., paper and from sequence data extracted from the 
Kabat database (Kabat, E. A. et al., Sequences of Proteins of 
Imm1mological Interest. 4th edition. U.S. Department of 
Health and Human Services. 1987). The three linker oligo­
nucleotides are described by Zhou et al. (1994, Nucleic Acids 
Res., 22: 888-889), all oligonucleotides used are detailed in 
Table 1. 
[0139] First, mRNA was isolated from peripheral blood 
lymphocytes and cDNA prepared for four repertoires of anti­
body genes IgD, IgM, IgK, and IgA, using four separate cDNA 
synthesis primers. VH genes were amplified from IgD and 
IgM primed cDNA, and VL genes were amplified from IgK 
and IgA primed cDNA. A portion of each set of amplified 
heavy chain or light chain DNA was then spliced with a 
separate piece of linker DNA encoding the 15 amino acids 
(Gly
4 
Ser)3 (Huston,]. S. etal. 1989, Gene, 77: 61 ). The 3'-end 
of the VH PCR products and the 5'-end of the VL PCR 
products overlap the linker sequence as a result of incorpo­
rating linker sequence in the JH, VK and VA family primer sets 
(Table 1). Each VH-linker or linker-VL DNA product was 
then spliced with either VH or VL DNA to produce the pri­
mary scFv product in a VH-linker-VL configuration. This 
scFv product was then amplified and cloned into pDM12 as a 
SfiI-NotI fragment, electroporated into TGJ and a concen­
trated PDCP stock prepared. 
mRNA Isolation and cDNA Synthesis. 
[0140] Human lymphocyte mRNA was purified as 
described in Example 2. Separate cDNA reactions were per­
formed with IGDCDNAFOR (SEQ ID No 37), IGM­
CDNAFOR (SEQ ID No 38), IGKCDNAFOR (SEQ ID No 
39) and IG11.CDNAFOR (SEQ ID No 40) oligonucleotides.
50 pmol of each primer was added to approximately 5 µg of
mRNA in 20 µl ofnuclease free water and heated to 70° C. for
5 minutes and cooled rapidly on ice, then made up to a final
reaction volume of 100 �tl containing 50 mM Iris pH 8.3, 75
mM KC!, 3 mM MgC12, 10 mM DTT, 0.5 mM dNTPs, and
2000 units of Superscript II reverse transcriptase (Lifo Tech­
nologies, Paisley, Scotland, U.K.). The reactions were incu­
bated at 37° C. for two hours, then heated to 95° C. for 5
minutes.
Primary PCRs. 
[ 0141 J For the primary PCR amplifications separate ampli­
fications were set up for each family specific primer with 
either an equimolar mixture of the JHFOR primer set (SEQ 
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ID Nos 41 to 44) for IgM and IgD cDNA, or with SCFVK­
FOR (SEQ ID No 51) or SCFVXFOR (SEQ ID No 52) for 
IgK or IgA cDNA respectively e.g. VHl BAK and JHFOR set; 
VK2BAK (SEQ ID No 54) and SCFVKFOR (SEQ ID No 51 ); 
V11.3aBAK (SEQ ID No 66) and SCFV11.FOR (SEQ ID No 52) 
etc. Thus, for IgM, IgD and IgK cDNA six separate reactions 
were set up, and seven for lgA cDNA. A 50 µI reaction mixture 
was prepared containing 2 �t! cDNA, 25 pmol of the appro­
priate FOR and BAK primers, 0.1 mM dNTPs, 2.5 units 
Taqplus DNA polymerase, and 1 x High Salt PCR reaction 
buffer (20 mM Tris-HCI pH 9.2, 60 mM KC!, 2 mM MgCl2) 
(Strata gene Ltd, Cambridge, U.K.). Reactions were amplified 
on a Techne Progene thermal cycler for 30 cycles of94° C., 1 
minute; 60° C., 1 minute; 72° C., 2 minutes, followed by 10 
minutes at 72° C. Fifty microlitres of all 25 reaction products 
were electrophoresed on an agarose gel, excised and products 
purified from the gel using a Geneclean II kit according to the 
manufacturers instmctions (Bio 101, La Jolla, Calif., U.S.A.). 
All sets oflgD, IgM, IgK or IgA reaction products were pooled 
to produce VH or VL DNA sets for each of the four reper­
toires. These were then adjusted to approximately 20 ng/µl. 
Preparation of Linker. 
[0142] Linker product was prepared from eight 100 µI reac­
tions containing 5 ng LINKAMP3T (SEQ ID No 76) template 
oligonucleotide, 50 pmol of LINKAMP3 (SEQ ID No 74) 
and LINKAMP5 (SEQ ID No 75) primers, 0.1 mM dNTPs, 
2.5 units Taqplus DNA polymerase, and lx High Salt PCR 
reaction buffer (20 mM Tris-HCI pH 9 .2, 60 mM KC!, 2 mM 
MgCl2) (Stratagene Ltd, Cambridge, U.K.). Reactions were 
amplified on a Techne Progene thermal cycler for 30 cycles of 
94° C., 1 minute; 60° C., 1 minute; 72° C., 1 minute, followed 
by 10 minutes at 72° C. All reaction product was electro­
phoresed on a 2% low melting point agarose gel, excised and 
products purified from the gel using a Mermaid kit according 
to the manufacturers instmctions (BiolOl, La Jolla, Calif., 
U.S.A.) and adjusted to 5 ng/µ1. 
First Stage Linking. 
[0143] Four linking reactions were prepared for each rep­
ertoire using 20 ng ofVH or VL DNA with 5 ng of Linker 
DNA in 100 µI reactions containing ( for IgM or IgD VH) 50 
pmol of LINKAMPFOR and VH1-6BAK set, or, 50 pmol 
LINKAMPBAK and either SCFVKFOR (IgK) or SCFVA­
FOR (IgA ), 0.1 mM dNTPs, 2.5 units Taq DNA polymerase, 
and lxPCR reaction buffer (10 mM Tris-HCI pH 9.0, 5 mM 
KC!, 0.01% Triton X@-100, 1.5 mM MgCU (Promega Ltd, 
Southampton, U.K.). Reactions were amplified on a Teclme 
Progene themial cycler for 30 cycles of94° C., 1 minute; 60° 
C., 1 minute; 72° C., 2 minutes, followed by 10 minutes at 72° 
C. Reaction products were electrophoresed on an agarose gel,
excised and products purified from the gel using a Geneclean
II kit according to the manufacturers instmctions (Bio 101, La 
Jolla, Calif., U.S.A.) and adjusted to 20 ng/µ1. 
Final Linking and Reamplification. 
[0144] To prepare the final scFv DNA products. five 100 µI 
reactions were performed for VH-LINKER plus VL DNA, 
and, five 100 µl reactions were performed for VH plus 
LINKER-VL DNA for each of the four final repertoires (IgM 
VH-VK, VH-V11.; IgD VH-VK, VH-V11.) as described in step 
( d) above using 20 ng of each component DNA as template.
Reaction products were electrophoresed on an agarose gel,
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excised and products purified from the gel using a Geneclean 
II kit according to the manufacturers instructions (Bio 101, La 
Jolla, Calif., U .S.A.) and adjusted to 20 ng/ µI. Each of the four 
repertoires was then re-amplified in a 100 µI reaction volume 
containing 2 ng of each linked product, with 50 pmol 
VHBAKl -6 (SEQ ID Nos 53 to 58) and either the JKFOR 
(SEQ ID Nos 66 to 70) or Jt,FOR (SEQ ID Nos 71 to 73) 
primer sets, in the presence of 0.1 mM dNTPs, 2.5 units Taq 
DNA polymerase, and 1 xPCR reaction buffer (10 mM Tris­
HCI pH 9.0, 5 mM KC!, 0.01% Triton X0-100, 1.5 mM 
MgCl2) (Promega Ltd, Southampton, U.K.). Thirty reactions 
were perfonned per repertoire to generate enough DNA for 
cloning. Reactions were amplified on a Techne Pro gene ther­
mal cycler for 25 cycles of 94 ° C., 1 minute; 65° C., 1 minute; 
72° C., 2 minutes, followed by 10 minutes at 72° C. Reaction 
products were phenol-chloroform extracted, ethanol precipi­
tated, vacuum dried and re-suspended in 80 �t! nuclease free 
water. 
Cloning into pDM12. 
[0145] Each of the four repertoires was SfiI-NotI digested, 
and electrophoresed on an agarose gel, excised and products 
purified from the gel using a Geneclean II kit according to the 
manufacturers instructions (Biol 01, La Jolla, Calif., U.S.A.). 
Each of the four repertoires was ligated overnight at 16° C. in 
140 µI with 10 µg of SfiI-NotI cut pDM12 prepared as in 
Example 2, and 12 units of T4 DNA ligase (Life Technolo­
gies, Paisley, Scotland, U.K.). After incubation the ligations 
were adjusted to 200 µI with nuclease free water, and DNA 
precipitated with 1 µI 20 mg/ml glycogen, 100 �tl 7.5M 
ammonium acetate and 900 µI ice-cold (-20° C.) absolute 
ethanol, vortex mixed and spun at 13,000 rpm for 20 minutes 
in a microfuge to pellet DNA. The pellets were washed with 
500 µI ice-cold 70% ethanol by centrifugation at 13,000 rpm 
for 2 minutes, then vacuum dried and re-suspended in 10 µI 
DEPC-treated water. 1 µI aliquots of each repertoire was 
electroporated into 80 µI E. coli (TG 1 ). Cells were grown in 1 
ml SOC medium per cuvette used for 1 hour at 37° C., and 
plated onto 2xTY agar plates supplemented with 1 % glucose 
and 100 �tg/ml ampicillin. 10-4, 10-5 and 10-6 dilutions of the
electroporated bacteria were also plated to assess library size. 
Colonies were allowed to grow overnight at 30° C. Cloning 
into SfiI-NotI digested pDM12 yielded anlgM-K/11.repertoire 
of l .16x l09 clones, and an IgD-KIA repertoire of l .2 lx l09 
clones. 
Preparation of PDCP Stock. 
[0146] Separate PDCP stocks were prepared for each rep­
ertoire library. The bacteria were then scraped off the plates 
into 30 ml 2xTY broth supplemented with 20% glycerol, 1 % 
glucose and 100 µg/ml ampicillin. 3 ml was added to a 50 ml 
2xTY culture broth supplemented with 1 % glucose and 100 
g/ml ampicillin and infected with 1011 kanamycin resistance 
units (kru) M13K07 helper phage at 37° C. for 30 minutes 
without shaking, then for 30 minutes with shaking at 200 rpm. 
Infected bacteria were transferred to 500 ml 2xTY broth 
supplemented with 25 µg/ml kanamycin, 100 µg/ml an1picil­
lin, and 20 �tM IPTG, then incubated overnight at 30° C., 
shaking at 200 rpm. Bacteria were pelleted at 4000 rpm for 20 
minutes in 50 ml Falcon tubes, and 80 ml 2.5M NaCl/20% 
PEG 6000 was added to 400 ml of particle supernatant, mixed 
vigorously and incubated on ice for 1 hour to precipitate 
PDCP particles. Particles were pelleted at 11 OOO rpm for 30 
minutes in 250 ml Oakridge tubes at 4 ° C. in a Sorvall RC5B 
centrifuge, then resuspended in 40 ml water and 8 ml 2.5M 
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NaCl/20% PEG 6000 added to reprecipitate particles, then 
incubated on ice for 20 minutes. Particles were again pelleted 
at 11 OOO rpm for 30 minutes in 50 ml Oakridge tubes at 4 ° C. 
in a Sorvall RC5B centrifuge, then resuspended in 5 ml PBS 
buffer, after removing all traces of PEG/NaCl with a pipette. 
Bacterial debris was removed by a 5 minute 13500 rpm spin 
in a microcentrifuge. The supernatant was filtered through a 
0.45 �un polysulfone syringe filter, adjusted to 20% glycerol 
and stored at -70° C. 
EXAMPLE 9 
Isolation of Binding Activity from a N-Terminal Dis-
play PDCP Library of Human scFvs 
[0147] The ability to select binding activities to a target of 
interest from a human antibody library is important due to the 
possibility of generating therapeutic human antibodies. In 
addition, such libraries allow the isolation of antibodies to 
targets which cannot be used for traditional methods of anti­
body generation due to toxicity, low il11llltmogenicity or ethi­
cal considerations. In this example we demonstrate the isola­
tion of specific binding activities against a peptide antigen 
from a PDCP library of scFvs from an un-immunised hlllllan. 
[0148] The generation of the library, used for the isolation 
of binding activities in this example, is described in Example 
8. 
[0149] Substance P is an eleven amino acid neuropeptide 
involved in inflammatory and pain responses in vivo. It has 
also been implicated in a variety of disorders such as psoriasis 
and asthma amongst others (Misery, L. 1997, Br. J. Dertma­
tol., 137: 843-850; Maggi, C. A. 1997, Regul. Pept. 70: 75-90; 
Choi, D. C. & Kwon, 0. J., 1998, Curr. Opin. Pulm. Med., 4: 
16-24). Human antibodies which neutralise this peptide may
therefore have some therapeutic potential. As this peptide is
too small to coat efficiently on a tube, as described in Example
3, selection of binding activities was performed in-solution,
using N-terminal biotinylated substance P and capturing
bound PDCP particles on streptavidin-coated magnetic
beads.
Enrichment for Substance P Binding PDCP Particles. 
[0150] An aliquot of approximately 1013 a.r.u. IgM and IgD 
scFv library stock was mixed with 1 µg biotinylated substance 
P in 800 µ14% BSA/0.1 % Tween 20/PBS, and allowed to bind 
for two hours at ambient temperature. Bound PDCPs were 
then captured onto 1 ml of BSA blocked streptavidin coated 
magnetic beads for 10 minutes at ambient temperature. The 
beads were captured to the side of the tube with a magnet 
(Promega), and unbound material discarded. The beads were 
washed eight times with 1 ml PBS/0.1 % Tween 20/10 µg/ml 
streptavidin, then two times with 1 ml of PBS by magnetic 
capture and removal of wash buffer. After the final wash 
bound PDCPs were eluted with 1 ml of freshly prepared 0.1 M 
triethylamine for 10 minutes, the beads were captured, and 
eluted particles transferred to 0.5 ml IM Tris-HCI pH 7.4. 
Neutralised particles were added to 10 ml log phase TG l E.
coli bacteria and incubated at 37° C. without shaking for 30 
minutes, then with shaking at 200 rpm for 30 minutes. 10-3• 
10-4 & 10-5 dilutions of the infected culture were prepared to 
estimate the number of particles recovered, and the remainder 
was spun at 4000 rpm for 10 minutes, and the pellet resus­
pended in 300 µI 2xTY medium by vortex mixing. Bacteria 
were plated onto 2xTY agar plates supplemented with 1 % 
glucose and 100 g/ml ampicillin. Colonies were allowed to 
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grow overnight at 30° C. A 100-fold concentrated PDCP
stock was prepared from a 200 ml amplified culture of these 
bacteria as described above, and 0.5 ml used in as second 
round of selection with 500 ng biotinylated substance P. For 
this round 100 µg/ml streptavidin was included in the wash 
buffer. 
ELISA Identification ofBinding Clones. 
[0151] Binding clones were identified by ELISA of96 indi­
vidual PDCP cultures prepared as described in Example 3 
from colonies recovered after the second round of selection. 
A Dynatech Immulon 4 ELISA plate was coated with 200 
ng/well streptavidin in 100 µI/well PBS for 1 hour at 37° C.
The plate was washed 3x200 µI/well PBS and incubated with 
long/well biotinylated substance P in 100 �tl/well PBS for 30 
minutes at 37° C. The plate was washed 3x200 µI/well PBS
and blocked for 1 hour at 3 7° C. with 200 �tl/well 2% Marvel
non-fat milk powder/PBS and then washed 2x200 µI/well 
PBS. 50 µI PDCP culture supernatant was added to each well 
containing 50 µI/well 4% Marvel/PBS, and allowed to bind 
for 1 hour at ambient temperature. The plate was washed three 
times with 200 µI/well PBS/0.1 % Tween 20, then three times 
with 200 �tl/well PBS. Bound PDCPs were detected with 100 
µI/well, 1:5000 diluted anti-M13-HRP cm�jugate (Pharma­
cia) in 2% Marvel/PBS for 1 hour at ambient temperature and 
the plate washed six times as above. The plate was developed 
for 10 minutes at ambient temperature with 100 µI/well 
freshly prepared TMB (3,3',5,5'-Tetraniethylbenzidine) sub­
strate buffer (0.005% H202, 0.1 mg/ml TMB in 24 mM citric 
acid/52 mM sodium phosphate buffer pH 5.2). The reaction 
was stopped with 100 µl/well 12.5% H2S04 and read at 450 
nm. Out of96 clones tested, 10 gave signals greater than twice 
background (background=0.05). 
Characterization of a Binding Clone. 
[0152] A 50-fold concentrated PDCP stock was prepared 
from a 100 ml amplified culture of a single ELISA positive 
clone as described above. 10 µI per well of this stock was 
tested in ELISA as described above for binding to streptavi­
din, streptavidin-biotinylated-substance P and streptavidin­
biotinylated-CGRP (N-terminal biotinylated). Binding was 
only observed in streptavidin-biotinylated-substance P 
coated wells indicating that binding was specific. In addition, 
binding to streptavidin-biotinylated substance P was com-
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pletely inhibited by incubating the PDCP with 1 µg/ml free 
substance P (see FIG. 8). The scFv VH (SEQ ID Nos 15 and 
16) and VL (SEQ ID Nos 17 and 18) DNA and amino acid
sequence was detem1ined by DNA sequencing with oligo­
nucleotides M13REV (SEQ ID No27) and ORSEQFOR
(SEQ ID No 36) and is shown in FIG. 9.
[0153] The results indicate that target binding activities can
be isolated from PDCP display libraries of human scFv frag­
ments.
EXAMPLE 10 
[0154] In another example the invention provides methods 
for screening a DNA library whose members require more 
than one chain for activity, as required by, for example, anti­
body Fab fragments for ligand binding. To increase the affin­
ity of an antibody of known heavy and light chain sequence, 
libraries of unknown light chains co-expressed with a known 
heavy chain are screened for higher affinity antibodies. The 
known heavy chain antibody DNA sequence is joined to a 
nucleotide sequence encoding a oestrogen receptor DNA 
binding domain in a phage vector which does not contain the 
oestrogen receptor HRE sequence. The antibody DNA 
sequence for the known heavy chain (VH and CHI )  gene is 
inserted in the 5' region of the oestrogen receptor DBD DNA, 
behind an appropriate promoter and translation sequences 
and a sequence encoding a signal peptide leader directing 
transport of the downstream fosion protein to the periplasmic 
space. The library of unknown light-chains (VL and CL) is 
expressed separately from a phagemid expression vector 
which also contains the oestrogen receptor HRE sequence. 
Thus when both heavy and light chains are expressed in the 
same host cell, following infection with the phage containing 
the heavy chain-DBD fusion, the light chain phagemid vector 
is preferentially packaged into mature phage particles as 
single stranded DNA, which is bound by the heavy chain­
DBD fusion protein during the packaging process. The light 
chain proteins are transported to the periplasm where they 
assemble with the heavy chain that is fused to the DBD 
protein as it exits the cell on the PDCP. In this example the 
DBD fusion protein and the HRE DNA sequences are not 
encoded on the same vector, the unknown peptide sequences 
are present on the san1e vector as the HRE sequence. Peptide 
display carrier packages (PDCP) which encode the protein of 
interest can then be selected by means of a ligand specific for 
the antibody. 
TABLE 1 
(i) Oligonucleotide primers used for human scFv library 
construction 
cDNA 
IgMCDNAFOR TGGAAGAGGCACGTTCTTTTCTTT 
IgDCDNAFOR CTCCTTCTTACTCTTGCTGGCGGT 
IgKCDNAFOR AGACTCTCCCCTGTTGAAGCTCTT 
IgACDNAFOR TGAAGATTCTGTAGGGGCCACTGTCTT 
JHFOR primers 
JH1-2FOR 
JH3FOR 
TGAACCGCCTCCACCTGAGGAGACGGTGACCAGGGTGCC 
TGAACCGCCTCCACCTGAAGAGACGGTGACCATTGTCCC 
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TABLE 1-continued 
JH4-5FOR TGAACCGCCTCCACCTGAGGAGACGGTGACCAGGGTTCC 
JH6FOR TGAACCGCCTCCACCTGAGGAGACGGTGACCGTGGTCCC 
VH familyBAKprimers 
VH1BAK 
VH2BAK 
VH3BAK 
VH4BAK 
VH5BAK 
VH6BAK 
SCFVKFOR 
SCFVAFOR 
VK 
VK1BAK 
VK2BAK 
VK3BAK 
VK4BAK 
VK5BAK 
VK6BAK 
TTTTTGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGGTGCAGTCTGG 
TTTTTGGCCCAGCCGGCCATGGCCCAGGTCAACTTAAGGGAGTCTGG 
TTTTTGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAGTCTGG 
TTTTTGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGCAGGAGTCGGG 
TTTTTGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGTTGCAGTCTGC 
TTTTTGGCCCAGCCGGCCATGGCCCAGGTACAGCTGCAGCAGTCAGG 
TTATTCGCGGCCGCCTAAACAGAGGCAGTTCCAGATTTC 
GTCACTTGCGGCCGCCTACAGTGTGGCCTTGTTGGCTTG 
TCTGGCGGTGGCGGATCGGACATCCAGATGACCCAGTCTCC 
TCTGGCGGTGGCGGATCGGATGTTGTGATGACTCAGTCTCC 
TCTGGCGGTGGCGGATCGGAAATTGTGTTGACGCAGTCTCC 
TCTGGCGGTGGCGGATCGGACATCGTGATGACCCAGTCTCC 
TCTGGCGGTGGCGGATCGGAAACGACACTCACGCAGTCTCC 
TCTGGCGGTGGCGGATCGGAAATTGTGCTGACTCAGTCTCC 
JK FOR primers 
JKlFOR 
JK2FOR 
JK3FOR 
JK4FOR 
JKSFOR 
TTCTCGTGCGGCCGCCTAACGTTTGATTTCCACCTTGGTCCC 
TTCTCGTGCGGCCGCCTAACGTTTGATCTCCAGCTTGGTCCC 
TTCTCGTGCGGCCGCCTAACGTTTGATATCCACTTTGGTCCC 
TTCTCGTGCGGCCGCCTAACGTTTGATCTCCACCTTGGTCCC 
TTCTCGTGCGGCCGCCTAACGTTTAATCTCCAGTCGTGTCCC 
VA family BAK primers 
VA1BAK 
VA2BAK 
TCTGGCGGTGGCGGATCGCAGTCTGTGTTGACGCAGCCGCC 
TCTGGCGGTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGC 
(ii) Oligonucleotide primers used for human scFv library 
construction 
VA3aBAK 
VA3bBAK 
VMBAK 
VASBAK 
VA6BAK 
JA primers 
JAlFOR 
J),2-3FOR 
JM-SFOR 
TCTGGCGGTGGCGGATCGTCCTATGTGCTGACTCAGCCACC 
TCTGGCGGTGGCGGATCGTCTTCTGAGCTGACTCAGGACCC 
TCTGGCGGTGGCGGATCGCACGTTATACTGACTCAACCGCC 
TCTGGCGGTGGCGGATCGCAGGCTGTGCTCACTCAGCCGTC 
TCTGGCGGTGGCGGATCGAATTTTATGCTGACTCAGCCCCA 
TTCTCGTGCGGCCGCCTAACCTAGGACGGTGACCTTGGTCCC 
TTCTCGTGCGGCCGCCTAACCTAGGACGGTCAGCTTGGTCCC 
TTCTCGTGCGGCCGCCTAACCTAAAACGGTGAGCTGGGTCCC 
Sep. 11, 2008 
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TABLE 1-continued 
Linker 
LINKAMP3 CGATCCGCCACCGCCAGA 
LINKAMP5 GTCTCCTCAGGTGGAGGC 
16 
LINKAMP3T CGATCCGCCACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCACCTGAGGAGAC 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 78
<210> SEQ ID NO 1 
<211> LENGTH: 521 
<212> TYPE: DNA 
<213> ORGANISM: Recombinant human oestrogen 
<220> FEATURE: 
<221> NAME/KEY: CDS
<222> LOCATION: (41) .. (475) 
<400> SEQUENCE: 1 
aagcttgcat gcaaattcta ttteaaggag acagtcataa atg aaa tac eta ttg 
Met Lys Tyr Leu Leu 
1 5 
cct acg gca gee get gga ttg tta tta ctc gcg gee cag ccg gee atg 
Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala Ala Gln Pro Ala Met 
10 15 20 
gee caa gtg cag ctg cag taa tag geg gee gca ggg gga gga ggg tee 
Ala Gln Val Gln Leu Gln Ala Ala Ala Gly Gly Gly Gly Ser 
25 30 35 
atg gaa tct gee aag gag act cgc tac tgt gca gtg tgc aat gac tat 
Met Glu Ser Ala Lys Glu Thr Arg Tyr Cys Ala Val Cys Asn Asp Tyr 
40 45 50 
get tea ggc tac cat tat gga gtc tgg tee tgt gag ggc tgc aag gee 
Ala Ser Gly Tyr His Tyr Gly Val Trp Ser Cys Glu Gly Cys Lys Ala 
55 60 65 
ttc ttc aag aga agt att caa gga cat aac gac tat atg tgt cca gee 
Phe Phe Lys Arg Ser Ile Gln Gly His Asn Asp Tyr Met Cys Pro Ala 
70 75 80 85 
ace aac cag tgc ace att gat aaa aac agg agg aag age tgc cag gee 
Thr Asn Gln Cys Thr Ile Asp Lys Asn Arg Arg Lys Ser Cys Gln Ala 
90 95 100 
tgc egg ctc cgt aaa tgc tac gaa gtg gga atg atg aaa ggt ggg ata 
Cys Arg Leu Arg Lys Cys Tyr Glu Val Gly Met Met Lys Gly Gly Ile 
105 110 115 
cga aaa gae cga aga gga ggg aga atg ttg aaa cac aag cgc eag aga 
Arg Lys Asp Arg Arg Gly Gly Arg Met Leu Lys His Lys Arg Gln Arg 
120 125 130 
gat gat ggg gag ggc agg ggt gaa gtg ggg tet tga taateaggtc 
Asp Asp Gly Glu Gly Arg Gly Glu Val Gly Ser 
135 140 145 
agagtgacct gagctaaaat aacacattca gaattc 
<210> SEQ ID NO 2 
<211> LENGTH: 27
<212> TYPE: PRT 
<213> ORGANISM: Recombinant human oestrogen
Sep. 11, 2008 
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151 
199 
247 
295 
343 
391 
439 
485 
521 
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<400> SEQUENCE: 2 
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 
1 5 10 15 
Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln 
20 25 
<210> SEQ ID NO 3 
<211> LENGTH: 115 
<212> TYPE: PRT 
<213> ORGANISM: Recombinant human oestrogen 
<400> SEQUENCE: 3 
Ala Ala Ala Gly Gly Gly Gly Ser Met Glu Ser Ala Lys Glu Thr Arg 
1 5 10 15 
Tyr Cys Ala Val Cys Asn Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val 
20 25 30 
Trp Ser Cys Glu Gly Cys Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly 
35 40 45 
His Asn Asp Tyr Met Cys Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys 
50 55 60 
Asn Arg Arg Lys Ser Cys Gln Ala Cys Arg Leu Arg Lys Cys Tyr Glu 
65 70 75 80 
Val Gly Met Met Lys Gly Gly Ile Arg Lys Asp Arg Arg Gly Gly Arg 
85 90 95 
Met Leu Lys His Lys Arg Gln Arg Asp Asp Gly Glu Gly Arg Gly Glu 
100 105 110 
Val Gly Ser 
115 
<210> SEQ ID NO 4 
<211> LENGTH: 102 
<212> TYPE: DNA
<213> ORGANISM: human 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (1) .. (102) 
<400> SEQUENCE: 4 
aaa cga act gtg get gca cca tct gtc ttc ate ttc ccg cca tct gat 48 
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 
1 5 10 15 
gag eag ttg aaa tct gga act gee tet gtt gtg tge ctg ctg aat aae 96 
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 
20 25 30 
ttc tat 102 
Phe Tyr 
<210> SEQ ID NO 5 
<211> LENGTH: 34 
<212> TYPE: PRT 
<213> ORGANISM: human 
<400> SEQUENCE: 5 
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 
1 5 10 15 
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 
20 25 30 
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Phe Tyr 
<210> SEQ ID NO 6 
<211> LENGTH: 150 
<212> TYPE: DNA
<213> ORGANISM: Human lymphocyte 
<220> FEATURE: 
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (150)
<400> SEQUENCE: 
atg gee cag CCC ace acg cgt ccg ggc caa ggg aca cga ctg gac att 48 
Met Ala Gln Pro Thr Thr Arg Pro Gly Gln Gly Thr Arg Leu Asp Ile 
1 5 10 15 
aaa cga act gtg get gca cca tct gtc ttc ate ttc ccg cca tct gat 96 
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 
20 25 30 
gag cag ttg aaa tct gga act gee tct gtt gtg tgc ctg ctg aat aac 144 
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 
35 40 45 
ttc tat 150 
Phe Tyr 
50 
<210> SEQ ID NO 7 
<211> LENGTH: 50 
<212> TYPE: PRT
<213> ORGANISM: Human lymphocyte 
<400> SEQUENCE: 7 
Met Ala Gln Pro Thr Thr Arg Pro Gly Gln Gly Thr Arg Leu Asp Ile 
1 5 10 15 
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 
20 25 30 
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 
35 40 45 
Phe Tyr 
50 
<210> SEQ ID NO 8 
<211> LENGTH: 150 
<212> TYPE: DNA
<213> ORGANISM: Human lymphocyte 
<220> FEATURE: 
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (150)
<400> SEQUENCE: 8 
atg gee cag tee cac cac gcg tee ggc gga ggg ace aag gtg gag ate 48 
Met Ala Gln Ser His His Ala Ser Gly Gly Gly Thr Lys Val Glu Ile 
1 5 10 15 
aaa cga act gtg get gca cca tct gtc ttc ate ttc ccg cca tct gat 96 
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 
20 25 30 
gag cag ttg aaa tct gga act gee tct gtt gtg tgc ctg ctg aat aac 144 
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 
35 40 45 
ttc tat 150 
Phe Tyr 
50 
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<210> SEQ ID NO 9 
<211> LENGTH: 50 
<212> TYPE: PRT
<213> ORGANISM: Human lymphocyte
<400> SEQUENCE: 9 
Met Ala Gln Ser His His Ala Ser Gly Gly Gly Thr Lys Val Glu Ile 
1 5 10 15 
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 
20 25 30 
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 
35 40 45 
Phe Tyr 
50 
<210> SEQ ID NO 10
<211> LENGTH: 566
<212> TYPE: DNA
<213> ORGANISM: Recombinant human oestrogen 
<220> FEATURE: 
<221> NAME/KEY: CDS 
<222> LOCATION: (41) .. (475) 
<400> SEQUENCE: 10
aagcttgcat gcaaattcta tttcaaggag acagtcataa atg aaa tac cta ttg 55 
Met Lys Tyr Leu Leu 
1 5 
cct acg gea gee get gga ttg tta tta etc geg gee eag ecg gee atg 103 
Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala Ala Gln Pro Ala Met 
10 15 20 
gee gag gtg caa ctg cag taa tag gcg gee gca ggg gga gga ggg tee 151 
Ala Glu Val Gln Leu Gln Ala Ala Ala Gly Gly Gly Gly Ser 
25 30 35 
atg gaa tct gee aag gag act cgc tac tgt gca gtg tgc aat gac tat 199 
Met Glu Ser Ala Lys Glu Thr Arg Tyr Cys Ala Val Cys Asn Asp Tyr 
40 45 50 
get tea ggc tac cat tat gga gtc tgg tee tgt gag ggc tgc aag gee 247 
Ala Ser Gly Tyr His Tyr Gly Val Trp Ser Cys Glu Gly Cys Lys Ala 
55 60 65 
ttc ttc aag aga agt att caa gga cat aac gac tat atg tgt cca gee 295 
Phe Phe Lys Arg Ser Ile Gln Gly His Asn Asp Tyr Met Cys Pro Ala 
70 75 80 85 
ace aac cag tgc ace att gat aaa aac agg agg aag age tgc eag gee 343 
Thr Asn Gln Cys Thr Ile Asp Lys Asn Arg Arg Lys Ser Cys Gln Ala 
90 95 100 
tgc egg ctc cgt aaa tgc tac gaa gtg gga atg atg aaa ggt ggg ata 391 
Cys Arg Leu Arg Lys Cys Tyr Glu Val Gly Met Met Lys Gly Gly Ile 
105 110 115 
cga aaa gac cga aga gga ggg aga atg ttg aaa cac aag cgc cag aga 439 
Arg Lys Asp Arg Arg Gly Gly Arg Met Leu Lys His Lys Arg Gln Arg 
120 125 130 
gat gat ggg gag ggc agg ggt gaa gtg ggg tct tga taatcaggtc 485 
Asp Asp Gly Glu Gly Arg Gly Glu Val Gly Ser 
135 140 145 
agagtgacct gagctaaaat aacacattca ggtcgacttg ggtcagtctg accgggacaa 545 
agttaatgta acctcgaatt c 566 
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<210> SEQ ID NO 11
<211> LENGTH: 27 
<212> TYPE: PRT 
<213> ORGANISM: Recombinant human oestrogen
<400> SEQUENCE: 11
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 
1 5 10 15 
Ala Gln Pro Ala Met Ala Glu Val Gln Leu Gln 
20 25 
<210> SEQ ID NO 12
<211> LENGTH: 115 
<212> TYPE: PRT 
<213> ORGANISM: Recombinant human oestrogen
<400> SEQUENCE: 12
Ala Ala Ala Gly Gly Gly Gly Ser Met Glu Ser Ala Lys Glu Thr Arg 
1 5 10 15 
Tyr Cys Ala Val Cys Asn Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val 
20 25 30 
Trp Ser Cys Glu Gly Cys Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly 
35 40 45 
His Asn Asp Tyr Met Cys Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys 
50 55 60 
Asn Arg Arg Lys Ser Cys Gln Ala Cys Arg Leu Arg Lys Cys Tyr Glu 
65 70 75 80 
Val Gly Met Met Lys Gly Gly Ile Arg Lys Asp Arg Arg Gly Gly Arg 
85 90 95 
Met Leu Lys His Lys Arg Gln Arg Asp Asp Gly Glu Gly Arg Gly Glu 
100 105 110 
Val Gly Ser 
115 
<210> SEQ ID NO 13
<211> LENGTH: 539 
<212> TYPE: DNA
<213> ORGANISM: Recombinant human oestrogen 
<220> FEATURE: 
<221> NAME/KEY: CDS
<222> LOCATION: (41) .. (478) 
<400> SEQUENCE: 13 
aagcttgcat gcaaattcta tttcaaggag acagtcataa atg aaa tac cta ttg 55 
Met Lys Tyr Leu Leu 
1 5 
cct acg gca gee get gga ttg tta tta ctc gcg gee cag ccg gca atg 103 
Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala Ala Gln Pro Ala Met 
10 15 20 
gee gag atg gaa tct gee aag gag act cgc tac tgt gca gtg tgc aat 151 
Ala Glu Met Glu Ser Ala Lys Glu Thr Arg Tyr Cys Ala Val Cys Asn 
25 30 35 
gac tat get tea ggc tac cat tat gga gtc tgg tee tgt gag ggc tgc 199 
Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val Trp Ser Cys Glu Gly Cys 
40 45 50 
aag gee ttc ttc aag aga agt att caa gga cat aac gac tat atg tgt 247 
Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly His Asn Asp Tyr Met Cys 
55 60 65 
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cca gee ace aac cag tgc ace att gat aaa aac agg agg aag age tgc 295 
Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys Asn Arg Arg Lys Ser Cys 
70 75 80 85 
cag gee tgc egg ctc cgt aaa tgc tac gaa gtg gga atg atg aaa ggt 343 
Gln Ala Cys Arg Leu Arg Lys Cys Tyr Glu Val Gly Met Met Lys Gly 
90 95 100 
999 ata cga aaa gae cga aga gga 999 aga atg ttg aaa cae aag cge 391 
Gly Ile Arg Lys Asp Arg Arg Gly Gly Arg Met Leu Lys His Lys Arg 
105 110 115 
cag aga gat gat 999 gag ggc agg ggt gaa gtg 999 tct 999 gga gga 439 
Gln Arg Asp Asp Gly Glu Gly Arg Gly Glu Val Gly Ser Gly Gly Gly 
120 125 1.30 
999 teg gee cag eeg gee etc etg eag etg geg gee gea taaetgattg 488 
Gly Ser Ala Gln Pro Ala Leu Leu Gln Leu Ala Ala Ala 
135 140 145 
agtcgacttg ggtcagtctg accgggacaa agttaatgta acctcgaatt c 539 
<210> SEQ ID NO 14
<211> LENGTH: 146
<212> TYPE: PRT
<213> ORGANISM: Recombinant human oestrogen
<400> SEQUENCE: 14
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala 
1 5 10 15 
Ala Gln Pro Ala Met Ala Glu Met Glu Ser Ala Lys Glu Thr Arg Tyr 
20 25 30 
Cys Ala Val Cys Asn Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val Trp 
35 40 45 
Ser Cys Glu Gly Cys Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly His 
50 55 60 
Asn Asp Tyr Met Cys Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys Asn 
65 70 75 80 
Arg Arg Lys Ser Cys Gln Ala Cys Arg Leu Arg Lys Cys Tyr Glu Val 
85 90 95 
Gly Met Met Lys Gly Gly Ile Arg Lys Asp Arg Arg Gly Gly Arg Met 
100 105 110 
Leu Lys His Lys Arg Gln Arg Asp Asp Gly Glu Gly Arg Gly Glu Val 
115 120 125 
Gly Ser Gly Gly Gly Gly Ser Ala Gln Pro Ala Leu Leu Gln Leu Ala 
130 135 140 
Ala Ala 
145 
<210> SEQ ID NO 15
<211> LENGTH: 372
<212> TYPE: DNA
<213> ORGANISM: Human
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (372)
<400> SEQUENCE: 15 
cag gta cag ctg cag cag tea ggg gga ggc gtg gtc cag cct ggg agg 48 
Gln Val Gln Leu Gln Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
US 2008/0220981 Al Sep. 11, 2008 
22 
-continued
tee ctg aga ctc tee tgt gca gee tcg gga ttc CCC ttt agt act tat 96 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Thr Tyr 
20 25 30 
ggc atg cac tgg cgc cag get gtc cca ggc aag ggg ctg gag tgg gtg 144 
Gly Met His Trp Arg Gln Ala Val Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
gca gtt ata tea tat gat gga agt aat aaa tac tac gca gac tee gtg 192 
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
50 55 60 
aag ggc cga ttc ace ate tee aga gac aat tee aag aac acg ttg tat 240 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
ctg caa atg aac age ctg aga get gag gac acg get gtg tat tac tgt 288 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
gcg aga gat tta gac CCC ace agg tat age agt ggc tgg gac act gac 336 
Ala Arg Asp Leu Asp Pro Thr Arg Tyr Ser Ser Gly Trp Asp Thr Asp 
100 105 110 
tac tgg ggc cag ggg cac ctg gtc act gtc tee tea 372 
Tyr Trp Gly Gln Gly His Leu Val Thr Val Ser Ser 
115 120 
<210> SEQ ID NO 16
<211> LENGTH: 124 
<212> TYPE: PRT 
<213> ORGANISM: Human 
<400> SEQUENCE: 16
Gln Val Gln Leu Gln Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Thr Tyr 
20 25 30 
Gly Met His Trp Arg Gln Ala Val Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Leu Asp Pro Thr Arg Tyr Ser Ser Gly Trp Asp Thr Asp 
100 105 110 
Tyr Trp Gly Gln Gly His Leu Val Thr Val Ser Ser 
115 120 
<210> SEQ ID NO 17 
<211> LENGTH: 327 
<212> TYPE: DNA
<213> ORGANISM: Human 
<220> FEATURE: 
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (327)
<400> SEQUENCE: 17
gaa acg aca ctc acg cag tct cca ggc ace ctg tct ttg tct ccg ggg 48 
Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1 5 10 15 
gaa aga gee ace ctc tee tgc agg gee agt cag aat att ggc age age 96 
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Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Gly Ser Ser 
20 25 30 
tee tta gee tgg tac caa cag aaa cct ggc cag get CCC agg ctc ctc 144 
Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
ate tat ggt gca tee ace agg gee act ggt ate cca gee agg ttc agt 192 
Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser 
50 55 60 
ggc agt ggg tea ggg aca caa ttc act ctc ace ate age age ctg cag 240 
Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Ser Leu Gln 
65 70 75 80 
tct gaa gat ttt gca gtt tat tac tgt cag cag tat aat ttc tgg cca 288 
Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Phe Trp Pro 
85 90 95 
ttc act ttt ggc cct ggg ace aag ctg gag ate aaa cgt 327 
Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys Arg 
100 105 
<210> SEQ ID NO 18 
<211> LENGTH: 109 
<212> TYPE: PRT 
<213> ORGANISM: Human 
<400> SEQUENCE: 18 
Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Asn Ile Gly Ser Ser 
20 25 30 
Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Ser Leu Gln 
65 70 75 80 
Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Phe Trp Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys Arg 
100 105 
<210> SEQ ID NO 19 
<211> LENGTH: 72 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 19 
ttttctgcag taataggcgg ccgcaggggg aggagggtcc atcgaaggtc gcgaagcaga 60 
gactgttgaa ag 72 
<210> SEQ ID NO 20
<211> LENGTH: 75 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
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<400> SEQUENCE: 20
ttttgaattc ttattaacca ccgaactgcg ggtgacgcca agcgcttgcg gccgttaaga 60 
ctccttatta cgcag 75 
<210> SEQ ID NO 21
<211> LENGTH: 32
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 21 
aaaagcggcc gcactggcct gagagannnn nn 
<210> SEQ ID NO 22 
<211> LENGTH: 16 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 22 
tcgacccacg cgtccg 
<210> SEQ ID NO 23
<211> LENGTH: 12 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 23
gggtgccgag gc 
<210> SEQ ID NO 24 
<211> LENGTH: 72 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 24 
32 
16 
12 
aaaagaattc tgaatgtgtt attttagctc aggtcactct gacctgatta tcaagacccc 60 
acttcacccc et 72 
<210> SEQ ID NO 25 
<211> LENGTH: 46 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 25 
aaaagcggcc gcagggggag gagggtccat ggaatctgcc aaggag 
<210> SEQ ID NO 26 
<211> LENGTH: 17 
46 
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<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
25 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 26 
gtaaaacgac ggccagt 
<210> SEQ ID NO 27 
<211> LENGTH: 20 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 27 
ggataacaat ttcacacagg 
<210> SEQ ID NO 28 
<211> LENGTH: 25 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 28 
aaagcggccg cactggcctg agaga 
<210> SEQ ID NO 29 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence, synthetic 
DNA 
<400> SEQUENCE: 29 
aaaaggccca gccggccatg gcccagccca ccacgcgtcc g 
<210> SEQ ID NO 30
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 30
aaaaggccca gccggccatg gcccagtccc accacgcgtc cg 
<210> SEQ ID NO 31 
<211> LENGTH: 43 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 31 
aaaaggccca gccggccatg gcccagtacc caccacgcgt ccg 
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<210> SEQ ID NO 32 
<211> LENGTH: 72 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
26 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 32 
aaaagaattc gaggttacat taactttgtt ccggtcagac tgacccaagt cgacctgaat 60 
gtgttatttt ag 72 
<210> SEQ ID NO 33 
<211> LENGTH: 32 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 33 
ccttggcaga ttccatctcg gccattgccg gc 
<210> SEQ ID NO 34 
<211> LENGTH: 31 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 34 
ccggcaatgg ccgagatgga atctgccaag g 
<210> SEQ ID NO 35 
<211> LENGTH: 86 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 35 
32 
31 
ttttgtcgac tcaatcagtt atgcggccgc cagctgcagg agggccggct gggccgaccc 60 
tcctccccca gaccccactt cacccc 86 
<210> SEQ ID NO 36 
<211> LENGTH: 20 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 36 
tgttgaaaca caagcgccag 
<210> SEQ ID NO 37 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
20 
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<400> SEQUENCE: 37 
tggaagaggc acgttctttt cttt 
<210> SEQ ID NO 38 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
27 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 38 
ctccttctta ctcttgctgg cggt 
<210> SEQ ID NO 39 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 39 
agactctccc ctgttgaagc tctt 
<210> SEQ ID NO 40 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 40 
tgaagattct gtaggggcca ctgtctt 
<210> SEQ ID NO 41 
<211> LENGTH: .39 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 41 
tgaaccgcct ccacctgagg agacggtgac cagggtgcc 
<210> SEQ ID NO 42 
<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 42 
tgaaccgcct ccacctgaag agacggtgac cattgtccc 
<210> SEQ ID NO 43 
<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
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28 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 43 
tgaaccgcct ccacctgagg agacggtgac cagggttcc 
<210> SEQ ID NO 44 
<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 44 
tgaaccgcct ccacctgagg agacggtgac cgtggtccc 
<210> SEQ ID NO 45 
<211> LENGTH: 47 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 45 
tttttggccc agccggccat ggcccaggtg cagctggtgc agtctgg 
<210> SEQ ID NO 46 
<211> LENGTH: 47 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 46 
tttttggccc agccggccat ggcccaggtc aacttaaggg agtctgg 
<210> SEQ ID NO 47 
<211> LENGTH: 47 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 47 
tttttggccc agccggccat ggccgaggtg cagctggtgg agtctgg 
<210> SEQ ID NO 48 
<211> LENGTH: 47 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 48 
tttttggccc agccggccat ggcccaggtg cagctgcagg agtcggg 
<210> SEQ ID NO 49 
<211> LENGTH: 47 
<212> TYPE: DNA 
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29 
-continued
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 49 
tttttggccc agccggccat ggccgaggtg cagctgttgc agtctgc 
<210> SEQ ID NO 50
<211> LENGTH: 47
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 50
tttttggccc agccggccat ggcccaggta cagctgcagc agtcagg 
<210> SEQ ID NO 51 
<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 51 
ttattcgcgg ccgcctaaac agaggcagtt ccagatttc 
<210> SEQ ID NO 52 
<211> LENGTH: 39 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 52 
gtcacttgcg gccgcctaca gtgtggcctt gttggcttg 
<210> SEQ ID NO 53 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 53 
tctggcggtg gcggatcgga catccagatg acccagtctc c 
<210> SEQ ID NO 54 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 54 
tctggcggtg gcggatcgga tgttgtgatg actcagtctc c 
<210> SEQ ID NO 55 
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<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
30 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 55 
tctggcggtg gcggatcgga aattgtgttg acgcagtctc c 
<210> SEQ ID NO 56 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 56 
tctggcggtg gcggatcgga catcgtgatg acccagtctc c 
<210> SEQ ID NO 57 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 57 
tctggcggtg gcggatcgga aacgacactc acgcagtctc c 
<210> SEQ ID NO 58 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 58 
tctggcggtg gcggatcgga aattgtgctg actcagtctc c 
<210> SEQ ID NO 59 
<211> LENGTH: 42 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence, synthetic 
DNA 
<400> SEQUENCE: 59 
ttctcgtgcg gccgcctaac gtttgatttc caccttggtc cc 
<210> SEQ ID NO 60 
<211> LENGTH: 42 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 60 
ttctcgtgcg gccgcctaac gtttgatctc cagcttggtc cc 
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<210> SEQ ID NO 61 
<211> LENGTH: 42 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
31 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 61 
ttctcgtgcg gccgcctaac gtttgatatc cactttggtc cc 
<210> SEQ ID NO 62 
<211> LENGTH: 42 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 62 
ttctcgtgcg gccgcctaac gtttgatctc caccttggtc cc 
<210> SEQ ID NO 63
<211> LENGTH: 42
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 63 
ttctcgtgcg gccgcctaac gtttaatctc cagtcgtgtc cc 
<210> SEQ ID NO 64 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 64 
tctggcggtg gcggatcgca gtctgtgttg acgcagccgc c 
<210> SEQ ID NO 65 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 65 
tctggcggtg gcggatcgca gtctgccctg actcagcctg c 
<210> SEQ ID NO 66 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 66 
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tctggcggtg gcggatcgtc ctatgtgctg actcagccac c 
<210> SEQ ID NO 67 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
32 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 67 
tctggcggtg gcggatcgtc ttctgagctg actcaggacc c 
<210> SEQ ID NO 68 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 68 
tctggcggtg gcggatcgca cgttatactg actcaaccgc c 
<210> SEQ ID NO 69 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic
DNA 
<400> SEQUENCE: 69 
tctggcggtg gcggatcgca ggctgtgctc actcagccgt c 
<210> SEQ ID NO 70
<211> LENGTH: 41
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence, synthetic 
DNA 
<400> SEQUENCE: 70
tctggcggtg gcggatcgaa ttttatgctg actcagcccc a 
<210> SEQ ID NO 71 
<211> LENGTH: 42 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence, synthetic 
DNA 
<400> SEQUENCE: 71 
ttctcgtgcg gccgcctaac ctaggacggt gaccttggtc cc 
<210> SEQ ID NO 72 
<211> LENGTH: 42 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
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<400> SEQUENCE: 72 
ttctcgtgcg gccgcctaac ctaggacggt cagcttggtc cc 
<210> SEQ ID NO 73
<211> LENGTH: 42 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
33 
-continued
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 73
ttctcgtgcg gccgcctaac ctaaaacggt gagctgggtc cc 
<210> SEQ ID NO 74 
<211> LENGTH: 18 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 74 
cgatccgcca ccgccaga 
<210> SEQ ID NO 75 
<211> LENGTH: 18 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 75 
gtctcctcag gtggaggc 
<210> SEQ ID NO 76 
<211> LENGTH: 54 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 76 
cgatccgcca ccgccagagc cacctccgcc tgaaccgcct ccacctgagg agac 
<210> SEQ ID NO 77 
<211> LENGTH: 38 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
DNA 
<400> SEQUENCE: 77 
tcaggtcaga gtgacctgag ctaaaataac acattcag 
<210> SEQ ID NO 78 
<211> LENGTH: 38 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: synthetic 
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34 
-continued
DNA 
<400> SEQUENCE: 78 
agtccagtct cactggactc gattttattg tgtaagtc 
1. A peptide display carrier package (PDCP), said package
comprising a recombinant polynucleotide-chimeric protein 
complex wherein the chimeric protein has a nucleotide bind­
ing portion and a target peptide portion, wherein said recom­
binant polynucleotide comprises a nucleotide sequence motif 
which is specifically bound by said nucleotide binding por­
tion, and wherein at least the chimeric protein-encoding por­
tion of the recombinant polynucleotide not bound by the 
chimeric protein nucleotide binding portion is protected by a 
binding moeity. 
2. A peptide display carrier package (PDCP) as claimed in
claim 1, wherein said chimeric protein-encoding portion of 
the recombinant polynucleotide not bound by the chimeric 
protein nucleotide binding portion is protected by a non­
sequence-specific protein. 
3. A peptide display carrier package (PDCP) as claimed in
claim 2, wherein said non-sequence-specific protein is a viral 
coat protein. 
4. A peptide display carrier package (PDCP) as claimed in
any one of claims 1 to 3, wherein said target peptide portion 
is displayed externally on the package. 
5. A peptide display carrier package (PDCP) as claimed in
any one of claims 1 to 4 wherein said recombinant polynucle­
otide includes a linker sequence between the nucleotide 
sequence encoding the nucleotide binding portion and the 
nucleotide sequence encoding the target peptide portion. 
6. A peptide display carrier package (PDCP) as claimed in
any one of claims 1 to 5 wherein said recombinant polynucle­
otide has two or more nucleotide sequence motifs each of 
which can be bound by the nucleotide binding portion of the 
chimeric protein. 
7. A peptide display carrier package (PDCP) as claimed in
any one of claims 1 to 6 wherein said nucleotide binding 
portion is a DNA binding domain of an oestrogen or proges­
terone receptor. 
8. A peptide display carrier package (PDCP) as claimed in
any one of claims 1 to 7 wherein said recombinant polynucle­
otide is bound to said chimeric protein as single stranded 
DNA. 
9. A peptide display carrier package (PDCP) as claimed in
any one of claims 1 to 8 wherein said target peptide portion is 
located at the N and/or C terminal of the chimeric protein. 
10. A peptide display carrier package (PDCP) as claimed in
any one of claims 1 to 9 which is produced in a host cell 
transfom1ed with said recombinant polynucleotide and 
extruded therefrom without lysis of the host cell. 
11. A recombinant polynucleotide comprising a nucleotide
sequence encoding a chimeric protein having a nucleotide 
binding portion operably linked to a target peptide portion, 
wherein said polynucleotide includes a specific nucleotide 
sequence motif which is bound by the nucleotide binding 
portion of said chimeric protein and further encoding a non­
sequence-specific nucleotide binding protein. 
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12. A recombinant polynucleotide as claimed in claim 11
wherein said non-sequence-specific nucleotide binding pro­
tein is a viral coat protein. 
13. A recombinant polynucleotide as claimed in either one
of claims 11 and 12 which includes a linker sequence between 
the nucleotide sequence encoding the nucleotide binding por­
tion and the nucleotide sequence encoding the target peptide 
portion. 
14. A recombinant polynucleotide as claimed in any one of
claims 11 to 13 which has two or more nucleotide sequence 
motifs each of which can be bound by the nucleotide binding 
portion of the chimeric protein. 
15. A recombinant polynucleotide as claimed in any one of
claims 11 to 14 wherein said nucleotide binding portion is a 
DNA binding domain of an oestrogen or progesterone recep­
tor. 
16. A recombinant polynucleotide as claimed in any one of
claims 11 to 15 wherein said recombinant polynucleotide is 
bound to said chimeric protein as single stranded DNA. 
17. A genetic construct or set of genetic constructs which
collectively comprises a polynucleotide having a sequence 
which includes: 
i) a sequence encoding a nucleotide binding portion able to
recognise and bind to a specific sequence motif; 
ii) the sequence motifrecognised and bound by the nucle­
otide binding portion encoded by (i);
iii) a restriction enzyme site which permits insertion of a
polynucleotide, said site being designed to operably link
said polynucleotide to the sequence encoding the nucle­
otide binding portion so that expression of the operably
linked polynucleotide sequences yields a chimeric pro­
tein; and
iv) a sequence encoding a nucleotide binding protein which
binds non-specifically to naked polynucleotide.
18. A genetic construct or set of genetic constructs as
claimed in claim 17 wherein a linker sequence is located 
between the nucleotide sequence encoding the nucleotide 
binding portion and the site for insertion of the polynucle­
otide. 
19. A genetic construct or set of genetic constructs as
claimed in either one of claims 17 and 18 which includes a 
vector pDM12, pDM14 or pDM16, deposited at NCIMB 
under Nos 40970, 40971 and 40972 respectively. 
20. A method of constructing a genetic library, said method
comprising: 
a) constructing multiple copies of a recombinant vector
comprising a polynucleotide sequence which encodes a
nucleotide binding portion able to recognise and bind to
a specific sequence motif;
b) operably linking each said vector to a polynucleotide
encoding a target polypeptide, such that expression of
said operably linked vector results in expression of a
chimeric protein comprising said target peptide and said
nucleotide binding portions; wherein said multiple cop-
US 2008/0220981 Al 
ies of said operably linked vectors collectively express a 
library of target peptide portions; 
c) transfonning host cells with the vectors of step b );
d) culturing the host cells of step c) under conditions suit­
able for expression of said chimeric protein;
e) providing a recombinant polynucleotide comprising the
nucleotide sequence motif specifically recognised by
the nucleotide binding portion and exposing this poly­
nucleotide to the chimeric protein of step
d) to yield a polynucleotide-chimeric protein complex; and
f) causing production of a non-sequence-specific moiety
able to bind to the non-protected portion of the poly­
nucleotide encoding the chimeric protein to form a pep­
tide display carrier package.
21. A method of screening a genetic library, said method
comprising: 
a) exposing the polynucleotide members of said library to
multiple copies of a genetic construct comprising a
nucleotide sequence encoding a nucleotide binding por­
tion able to recognise and bind to a specific sequence
motif, under conditions suitable for the polynucleotides
of said library each to be individually ligated into one
copy of said genetic construct, to create a library of
recombinant polynucleotides;
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b) exposing said recombinant polynucleotides to a popu­
lation of host cells. under conditions suitable for trans­
fonnation of said host cells by said recombinant poly­
nucleotides;
c) selecting for transformed host cells;
d) exposing said transformed host cells to conditions suit­
able for expression of said recombinant polynucleotide
to yield a chimeric protein; and
e) providing a recombinant polynucleotide comprising the
nucleotide sequence motif specifically recognised by 
the nucleotide binding portion and exposing this poly­
nucleotide to the chimeric protein of step
d) to yield a polynucleotide-chimeric protein complex;
f) protecting any exposed portions of the polynucleotide in
the complex of step e) to form a peptide display carrier
package; and
g) screening said peptide display carrier package to select
only those packages displaying a target peptide portion
having the characteristics required.
22. A method as claimed in claim 21 wherein the peptide
display package carrier is extruded from the host cell without 
lysis thereof. 
23. A polynucleotide comprising a nucleotide sequence
substantially as set out in SEQ ID No. 15 or SEQ ID No. 17. 
* * * * *
